

-> b reg  
 FILE 'REGISTRY' ENTERED AT 14:13:59 ON 06 MAY 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAY 2008 HIGHEST RN 1019372-76-9  
 DICTIONARY FILE UPDATES: 5 MAY 2008 HIGHEST RN 1019372-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

-> d que sta l11

L6 STR  
 10 9  
 G1 G3  
 |||  
 Cy~N~C~G1~G2~C~Hy~Hy  
 1 2 3 4 5 6 7 8

VAR G1=N/O/S

REP G2=(1-2) C

VAR G3=O/S

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E5 C E1 N AT 7

ECOUNT IS E5 C E1 N AT 8

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

L8 419318 SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5/ES

L11 101 SEA FILE=REGISTRY SUB=L8 SSS FUL L6

100.0% PROCESSED 177648 ITERATIONS

101 ANSWERS

SEARCH TIME: 00.00.02

-> b hcap

FILE 'HCAPIUS' ENTERED AT 14:14:11 ON 06 MAY 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 May 2008 VOL 148 ISS 19  
FILE LAST UPDATED: 5 May 2008 (20080505/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d bib abs hitrn fhltstr l16 tot




```
=> d bib abs hitstr 1167 tot  
L167 NOT FOUND
```

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

```
=> d bib abs hitstr 117 tot
```




117 ANSHER 1 OF 8 NCPALUS OBERDICK 2008 ACS on STM (Continued)



RD 63711-10-3 NCPALUS  
 CN Drex. N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbamoyl]-3-[(4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl]-N'-[(4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl-3-methyl-2-oxopiperidine-1-carboxamide (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-10-4 NCPALUS  
 CN Drex. N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbamoyl]-3-[(4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl]-N'-phenyl-5-piperidinyl-3-methyl-2-oxopiperidine-1-carboxamide (CA INDEX NAME)


Absolute stereochemistry.

117 ANSHER 1 OF 8 NCPALUS OBERDICK 2008 ACS on STM (Continued)



RD 63711-10-5 NCPALUS  
 CN Drex. N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbamoyl]-3-[(4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl]-N'-phenyl-5-piperidinyl-3-methyl-2-oxopiperidine-1-carboxamide (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-10-6 NCPALUS  
 CN Drex. N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbamoyl]-3-[(4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl]-N'-[4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl-3-methyl-2-oxopiperidine-1-carboxamide (CA INDEX NAME)


Absolute stereochemistry.

117 ANSHER 1 OF 8 NCPALUS OBERDICK 2008 ACS on STM (Continued)



RD 63711-10-7 NCPALUS  
 CN Drex. N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbamoyl]-3-[(4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl]-N'-[4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl-3-methyl-2-oxopiperidine-1-carboxamide (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-10-8 NCPALUS  
 CN Drex. N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbamoyl]-3-[(4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl]-N'-[4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl-3-methyl-2-oxopiperidine-1-carboxamide (CA INDEX NAME)


Absolute stereochemistry.

117 ANSHER 1 OF 8 NCPALUS OBERDICK 2008 ACS on STM (Continued)



RD 63711-10-9 NCPALUS  
 CN Drex. N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbamoyl]-3-[(4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl]-N'-[4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl-3-methyl-2-oxopiperidine-1-carboxamide (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-10-10 NCPALUS  
 CN Drex. N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbamoyl]-3-[(4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl]-N'-[4-phenyl-3-methyl-2-oxopiperidin-2-yl)carbamoyl]-5-piperidinyl-3-methyl-2-oxopiperidine-1-carboxamide (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-82-5 HCAPLUS  
 CN Dose: Nc1ccc(cc1)C(=O)N[C@H]2CC[C@@H](C(=O)N[C@H]3CC[C@@H](C(=O)Nc4ccccc4)CC3)CC2  
 (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-82-6 HCAPLUS  
 CN Dose: Nc1ccc(cc1)C(=O)N[C@H]2CC[C@@H](C(=O)N[C@H]3CC[C@@H](C(=O)Nc4ccccc4)CC3)CC2  
 (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-90-8 HCAPLUS  
 CN Dose: Clc1ccc(cc1Cl)C(=O)N[C@H]2CC[C@@H](C(=O)N[C@H]3CC[C@@H](C(=O)Nc4ccccc4)CC3)CC2  
 (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-91-0 HCAPLUS  
 CN Dose: Fc1ccc(cc1)C(=O)N[C@H]2CC[C@@H](C(=O)N[C@H]3CC[C@@H](C(=O)Nc4ccccc4)CC3)CC2  
 (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)




RD 63711-92-3 HCAPLUS  
 CN Dose: O=C1CC[C@H](C(=O)N[C@H]2CC[C@@H](C(=O)N[C@H]3CC[C@@H](C(=O)Nc4ccccc4)CC3)CC2)CC1  
 (CA INDEX NAME)

Absolute stereochemistry.




RD 63711-93-2 HCAPLUS  
 CN Dose: O=C1CC[C@H](C(=O)N[C@H]2CC[C@@H](C(=O)N[C@H]3CC[C@@H](C(=O)Nc4ccccc4)CC3)CC2)CC1  
 (CA INDEX NAME)

Absolute stereochemistry.




117 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-94-8 HCAPLUS  
 CN Dose: O=C1CC[C@H](C(=O)N[C@H]2CC[C@@H](C(=O)N[C@H]3CC[C@@H](C(=O)Nc4ccccc4)CC3)CC2)CC1  
 (CA INDEX NAME)

Absolute stereochemistry.



RD 63711-96-4 HCAPLUS  
 CN Dose: O=C1CC[C@H](C(=O)N[C@H]2CC[C@@H](C(=O)N[C@H]3CC[C@@H](C(=O)Nc4ccccc4)CC3)CC2)CC1  
 (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-96-5 HCAPLUS  
 CN Dose: O=C1CC[C@H](C(=O)N[C@H]2CC[C@@H](C(=O)N[C@H]3CC[C@@H](C(=O)Nc4ccccc4)CC3)CC2)CC1  
 (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-47-6 NOVELUS  
 CN Dose: M-118-1-(1,4'-bipiperidin-3'-ylacetonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-morphoyl-N'-[4-(3,4-dichlorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-48-6 NOVELUS  
 CN Dose: M-118-1-(1,4'-bipiperidin-3'-ylacetonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-morphoyl-N'-[4-(3-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-49-6 NOVELUS  
 CN Dose: M-118-1-(1,4'-bipiperidin-3'-ylacetonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-morphoyl-N'-[4-(3-chlorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-50-6 NOVELUS  
 CN Dose: M-118-1-(1,4'-bipiperidin-3'-ylacetonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-morphoyl-N'-[4-(3-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-51-6 NOVELUS  
 CN Dose: M-118-1-(1,4'-bipiperidin-3'-ylacetonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-morphoyl-N'-[4-(3-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-52-6 NOVELUS  
 CN Dose: M-118-1-(1,4'-bipiperidin-3'-ylacetonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-morphoyl-N'-[4-(3-chlorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-54-8 NOVELUS  
 CN Dose: M-118-1-(1,4'-bipiperidin-3'-ylacetonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-morphoyl-N'-[4-(3-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RD 63711-55-6 NOVELUS  
 CN Dose: M-118-1-(1,4'-bipiperidin-3'-ylacetonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-morphoyl-N'-[4-(3-chlorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 R04PUSL OPIR10KT 2008 ACS on B3H (Continued)



RD 63711-18-5 R04PUSL  
 CD Data:  $M = [148 - 1 - (1,4\text{-bipiperidin-1'-yl}(\text{benzoyl})-3\text{-}[(\text{4-(1,4-dihydro-2-oxo-3(2H)-quinoxalonyl)-5-piperidinyl}-3\text{-}(\text{prop-1-yn-1-yl})-2\text{-chlorophenyl}) - (CA INDEX NAME)]$


Absolute stereochemistry.



RD 63711-19-3 R04PUSL  
 CD Data:  $M = [148 - 1 - (1,4\text{-bipiperidin-1'-yl}(\text{benzoyl})-3\text{-}[(\text{4-(1,4-dihydro-2-oxo-3(2H)-quinoxalonyl)-5-piperidinyl}-3\text{-}(\text{prop-1-yn-1-yl})-2\text{-chlorophenyl}) - (CA INDEX NAME)]$


Absolute stereochemistry.

117 ANSWER 1 OF 8 R04PUSL OPIR10KT 2008 ACS on B3H (Continued)



RD 63712-10-6 R04PUSL  
 CD Data:  $M = [148 - 1 - (1,4\text{-bipiperidin-1'-yl}(\text{benzoyl})-3\text{-}[(\text{4-(1,4-dihydro-2-oxo-3(2H)-quinoxalonyl)-5-piperidinyl}-3\text{-}(\text{prop-1-yn-1-yl})-2\text{-chlorophenyl}) - (CA INDEX NAME)]$


Absolute stereochemistry.



RD 63712-11-7 R04PUSL  
 CD Data:  $M = [148 - 1 - (1,4\text{-bipiperidin-1'-yl}(\text{benzoyl})-3\text{-}[(\text{4-(1,4-dihydro-2-oxo-3(2H)-quinoxalonyl)-5-piperidinyl}-3\text{-}(\text{prop-1-yn-1-yl})-2\text{-chlorophenyl}) - (CA INDEX NAME)]$


Absolute stereochemistry.

117 ANSWER 1 OF 8 R04PUSL OPIR10KT 2008 ACS on B3H (Continued)



RD 63713-12-8 R04PUSL  
 CD Data:  $M = [148 - 1 - (1,4\text{-bipiperidin-1'-yl}(\text{benzoyl})-3\text{-}[(\text{4-(1,4-dihydro-2-oxo-3(2H)-quinoxalonyl)-5-piperidinyl}-3\text{-}(\text{prop-1-yn-1-yl})-2\text{-chlorophenyl}) - (CA INDEX NAME)]$


Absolute stereochemistry.



RD 63713-13-9 R04PUSL  
 CD Data:  $M = [148 - 1 - (1,4\text{-bipiperidin-1'-yl}(\text{benzoyl})-3\text{-}[(\text{4-(1,4-dihydro-2-oxo-3(2H)-quinoxalonyl)-5-piperidinyl}-3\text{-}(\text{prop-1-yn-1-yl})-2\text{-chlorophenyl}) - (CA INDEX NAME)]$


Absolute stereochemistry.

117 ANSWER 1 OF 8 R04PUSL OPIR10KT 2008 ACS on B3H (Continued)



RD 63713-14-0 R04PUSL  
 CD Data:  $M = [148 - 1 - (1,4\text{-bipiperidin-1'-yl}(\text{benzoyl})-3\text{-}[(\text{4-(1,4-dihydro-2-oxo-3(2H)-quinoxalonyl)-5-piperidinyl}-3\text{-}(\text{prop-1-yn-1-yl})-2\text{-chlorophenyl}) - (CA INDEX NAME)]$


Absolute stereochemistry.



RD 63713-15-1 R04PUSL  
 CD Data:  $M = [148 - 1 - (1,4\text{-bipiperidin-1'-yl}(\text{benzoyl})-3\text{-}[(\text{4-(1,4-dihydro-2-oxo-3(2H)-quinoxalonyl)-5-piperidinyl}-3\text{-}(\text{prop-1-yn-1-yl})-2\text{-chlorophenyl}) - (CA INDEX NAME)]$


Absolute stereochemistry.

117 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on BTH (Continued)



RD 63712-14-3 HCAPLUS  
CN O=C(Nc1ccc(Cl)cc1)C[C@H](C(=O)N2CCCCC2)N3CCCCC3C(=O)c4ccc5ccccc54  
(CA INDEX NAME)


Absolute stereochemistry.



RD 63712-17-3 HCAPLUS  
CN O=C(Nc1ccc(Br)cc1)C[C@H](C(=O)N2CCCCC2)N3CCCCC3C(=O)c4ccc5ccccc54  
(CA INDEX NAME)


Absolute stereochemistry

117 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on BTH (Continued)



RD 63712-19-6 HCAPLUS  
CN O=C(Nc1ccc(F)cc1)C[C@H](C(=O)N2CCCCC2)N3CCCCC3C(=O)c4ccc5ccccc54  
(CA INDEX NAME)


Absolute stereochemistry.



RD 63712-20-8 HCAPLUS  
CN O=C(Nc1ccc(C)cc1)C[C@H](C(=O)N2CCCCC2)N3CCCCC3C(=O)c4ccc5ccccc54  
(CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on BTH (Continued)



RD 63712-21-3 HCAPLUS  
CN O=C(Nc1ccc(C)cc1)C[C@H](C(=O)N2CCCCC2)N3CCCCC3C(=O)c4ccc5ccccc54  
(CA INDEX NAME)


Absolute stereochemistry.



RD 63712-22-3 HCAPLUS  
CN O=C(Nc1ccc(C)cc1)C[C@H](C(=O)N2CCCCC2)N3CCCCC3C(=O)c4ccc5ccccc54  
(CA INDEX NAME)


Absolute stereochemistry

117 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on BTH (Continued)



RD 63712-24-2 HCAPLUS  
CN O=C(Nc1ccc(C)cc1)C[C@H](C(=O)N2CCCCC2)N3CCCCC3C(=O)c4ccc5ccccc54  
(CA INDEX NAME)


Absolute stereochemistry.



RD 63712-26-2 HCAPLUS  
CN O=C(Nc1ccc(C)cc1)C[C@H](C(=O)N2CCCCC2)N3CCCCC3C(=O)c4ccc5ccccc54  
(CA INDEX NAME)


Absolute stereochemistry

117 ANSWER 1 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635712-14-4 NOVELUS  
 CN DData: N=1180-1-(1,4'-bipiperidin-1'-yl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-2-yl)-5-methyl-1H-pyrazol-5-yl)-1H-pyrazole-5-carboxamide (CA INDEX NAME)


Absolute stereochemistry.



RD 635712-17-6 NOVELUS  
 CN DData: N=1180-1-(1,4'-bipiperidin-1'-yl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-2-yl)-5-methyl-1H-pyrazol-5-yl)-1H-pyrazole-5-carboxamide (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635712-18-6 NOVELUS  
 CN DData: N=1180-1-(1,4'-bipiperidin-1'-yl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-2-yl)-5-methyl-1H-pyrazol-5-yl)-1H-pyrazole-5-carboxamide (CA INDEX NAME)


Absolute stereochemistry.



RD 635712-19-7 NOVELUS  
 CN DData: N=1180-1-(1,4'-bipiperidin-1'-yl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-2-yl)-5-methyl-1H-pyrazol-5-yl)-1H-pyrazole-5-carboxamide (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635712-20-0 NOVELUS  
 CN DData: N=1180-1-(1,4'-bipiperidin-1'-yl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-2-yl)-5-methyl-1H-pyrazol-5-yl)-1H-pyrazole-5-carboxamide (CA INDEX NAME)


Absolute stereochemistry.



RD 635712-20-1 NOVELUS  
 CN DData: N=1180-1-(1,4'-bipiperidin-1'-yl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-2-yl)-5-methyl-1H-pyrazol-5-yl)-1H-pyrazole-5-carboxamide (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 1 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635712-21-2 NOVELUS  
 CN DData: N=1180-1-(1,4'-bipiperidin-1'-yl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-2-yl)-5-methyl-1H-pyrazol-5-yl)-1H-pyrazole-5-carboxamide (CA INDEX NAME)

Absolute stereochemistry.




RD 635712-22-3 NOVELUS  
 CN DData: N=1180-1-(1,4'-bipiperidin-1'-yl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-2-yl)-5-methyl-1H-pyrazol-5-yl)-1H-pyrazole-5-carboxamide (CA INDEX NAME)

Absolute stereochemistry.




117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 639711-12-8 NOAPLUS  
 CW Dose: 9-[(1S,4S)-1-((1S,4S)-4-dihydro-2-mono-3(2H)-quinolinolyl)-5-piperidinyl-3-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-yl]-N-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-amine (CA INDEX NAME)


Absolute stereochemistry.



RD 639711-16-2 NOAPLUS  
 CW Dose: 9-[(1S,4S)-1-((1S,4S)-4-dihydro-2-mono-3(2H)-quinolinolyl)-5-piperidinyl-3-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-yl]-N-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-amine (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 639711-16-1 NOAPLUS  
 CW Dose: 9-[(1S,4S)-1-((1S,4S)-4-dihydro-2-mono-3(2H)-quinolinolyl)-5-piperidinyl-3-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-yl]-N-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-amine (CA INDEX NAME)


Absolute stereochemistry.



RD 639711-73-3 NOAPLUS  
 CW Dose: 9-[(1S,4S)-1-((1S,4S)-4-dihydro-2-mono-3(2H)-quinolinolyl)-5-piperidinyl-3-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-yl]-N-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-amine (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)




RD 639711-16-3 NOAPLUS  
 CW Dose: 9-[(1S,4S)-1-((1S,4S)-4-dihydro-2-mono-3(2H)-quinolinolyl)-5-piperidinyl-3-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-yl]-N-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-amine (CA INDEX NAME)

Absolute stereochemistry.



RD 639711-16-4 NOAPLUS  
 CW Dose: 9-[(1S,4S)-1-((1S,4S)-4-dihydro-2-mono-3(2H)-quinolinolyl)-5-piperidinyl-3-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-yl]-N-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-amine (CA INDEX NAME)


Absolute stereochemistry.



117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)


RD 639711-43-3 NOAPLUS  
 CW Dose: 9-[(1S,4S)-1-((1S,4S)-4-dihydro-2-mono-3(2H)-quinolinolyl)-5-piperidinyl-3-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-yl]-N-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-amine (CA INDEX NAME)

Absolute stereochemistry.



RD 639711-43-4 NOAPLUS  
 CW Dose: 9-[(1S,4S)-1-((1S,4S)-4-dihydro-2-mono-3(2H)-quinolinolyl)-5-piperidinyl-3-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-yl]-N-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-amine (CA INDEX NAME)


Absolute stereochemistry.



RD 639711-43-5 NOAPLUS  
 CW Dose: 9-[(1S,4S)-1-((1S,4S)-4-dihydro-2-mono-3(2H)-quinolinolyl)-5-piperidinyl-3-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-yl]-N-methyl-4-phenyl-1H-1,2,4-oxadiazol-5-amine (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-84-1 NOAPLUS  
CN W=([18]-1-(1,4'-bipiperidin-3'-yl)glutonyl)-3-[(1,4,6-dihydro-2-mono-3,2H-quinoxalin-1'-yl)-piperidin-3-propargyl]-N''-(2,3-dichlorophenyl)- (CN INDEX NAME)


Absolute stereochemistry.



RD 63711-86-2 NOAPLUS  
CN W=([18]-1-(1,4'-bipiperidin-3'-yl)glutonyl)-3-[(1,4,6-dihydro-2-mono-3,2H-quinoxalin-1'-yl)-piperidin-3-propargyl]-N''-(2,3-dichlorophenyl)- (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-87-4 NOAPLUS  
CN W=([18]-1-(1,4'-bipiperidin-3'-yl)glutonyl)-3-[(1,4,6-dihydro-2-mono-3,2H-quinoxalin-1'-yl)-piperidin-3-propargyl]-N''-(2,3-dichlorophenyl)- (CN INDEX NAME)


Absolute stereochemistry.



RD 63711-88-5 NOAPLUS  
CN W=([18]-1-(1,4'-bipiperidin-3'-yl)glutonyl)-3-[(1,4,6-dihydro-2-mono-3,2H-quinoxalin-1'-yl)-piperidin-3-propargyl]-N''-(2,3-dichlorophenyl)- (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-89-6 NOAPLUS  
CN W=([18]-1-(1,4'-bipiperidin-3'-yl)glutonyl)-3-[(1,4,6-dihydro-2-mono-3,2H-quinoxalin-1'-yl)-piperidin-3-propargyl]-N''-(1,4-dichloro-2-trifluoromethylphenyl)- (CN INDEX NAME)


Absolute stereochemistry.



RD 63711-90-8 NOAPLUS  
CN W=([18]-1-(1,4'-bipiperidin-3'-yl)glutonyl)-3-[(1,4,6-dihydro-2-mono-3,2H-quinoxalin-1'-yl)-piperidin-3-propargyl]-N''-(1,4-dichloro-2-trifluoromethylphenyl)- (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)




RD 63711-91-0 NOAPLUS  
CN W=([18]-1-(1,4'-bipiperidin-3'-yl)glutonyl)-3-[(1,4,6-dihydro-2-mono-3,2H-quinoxalin-1'-yl)-piperidin-3-propargyl]-N''-(1,4-dichloro-2-phenylphenyl)- (CN INDEX NAME)

Absolute stereochemistry.



RD 63711-92-1 NOAPLUS  
CN W=([18]-1-(1,4'-bipiperidin-3'-yl)glutonyl)-3-[(1,4,6-dihydro-2-mono-3,2H-quinoxalin-1'-yl)-piperidin-3-propargyl]-N''-(1,4-dichloro-2-phenylphenyl)- (CN INDEX NAME)


Absolute stereochemistry.



117 ANSWER 2 OF 8 RCPAPUS COPYRIGHT 2008 ACS on STM (Continued)


RN 63711-43-0 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,5-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 63711-44-3 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,5-dimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 63711-45-6 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



117 ANSWER 2 OF 8 RCPAPUS COPYRIGHT 2008 ACS on STM (Continued)


RN 63711-46-3 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,4-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 63711-48-3 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,4-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 63711-49-6 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,4-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



117 ANSWER 2 OF 8 RCPAPUS COPYRIGHT 2008 ACS on STM (Continued)


RN 63711-46-3 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,5-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 63711-47-6 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,4-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 63711-47-6 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,4-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



117 ANSWER 2 OF 8 RCPAPUS COPYRIGHT 2008 ACS on STM (Continued)


RN 63711-48-3 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,4-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 63711-49-6 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,4-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 63711-49-6 RCPAPUS  
CN Drex. W-1181-1-(1,4'-bipiperidin-1'-yl-carbonyl)-3-[6-(1,4-dihydro-2-methyl-2H-pyran-5-yl)-5-piperidinyl]-3-methyl-1H-(1,4-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)




Absolute stereochemistry.




Absolute stereochemistry.

117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)




Absolute stereochemistry.




Absolute stereochemistry.

117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)




Absolute stereochemistry.




Absolute stereochemistry.

117 ANSWER 2 OF 8 NOAPLUS COPYRIGHT 2008 ACS on STM (Continued)




Absolute stereochemistry.




Absolute stereochemistry.

117 ANSWER 2 OF 8 KAPLUS COPYRIGHT 2004 ACS on STM (Continued)



RD 63712-12-9 KAPLUS  
CN Draw. N-[[12a-1-[(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-oxo-3,4-dihydroquinolin-2-yl)-piperidin-3-onyl]-4'-piperidinyl]-4-phenyl]-4'-piperidinyl-1'-carboxamide (CN INDEX NAME)


Absolute stereochemistry.



RD 63712-14-0 KAPLUS  
CN Draw. N-[[12a-1-[(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-oxo-3,4-dihydroquinolin-2-yl)-piperidin-3-onyl]-4'-piperidinyl]-4'-piperidinyl]-4'-piperidinyl-1'-carboxamide (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 2 OF 8 KAPLUS COPYRIGHT 2004 ACS on STM (Continued)



RD 63712-15-1 KAPLUS  
CN Draw. N-[[12a-1-[(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-oxo-3,4-dihydroquinolin-2-yl)-piperidin-3-onyl]-4'-piperidinyl]-4'-piperidinyl]-4'-piperidinyl-1'-carboxamide (CN INDEX NAME)


Absolute stereochemistry.



RD 63712-16-0 KAPLUS  
CN Draw. N-[[12a-1-[(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-oxo-3,4-dihydroquinolin-2-yl)-piperidin-3-onyl]-4'-piperidinyl]-4'-piperidinyl]-4'-piperidinyl-1'-carboxamide (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 2 OF 8 KAPLUS COPYRIGHT 2004 ACS on STM (Continued)



RD 63712-17-3 KAPLUS  
CN Draw. N-[[12a-1-[(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-oxo-3,4-dihydroquinolin-2-yl)-piperidin-3-onyl]-4'-piperidinyl]-4'-piperidinyl]-4'-piperidinyl-1'-carboxamide (CN INDEX NAME)


Absolute stereochemistry.



RD 63712-17-6 KAPLUS  
CN Draw. N-[[12a-1-[(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-oxo-3,4-dihydroquinolin-2-yl)-piperidin-3-onyl]-4'-piperidinyl]-4'-piperidinyl]-4'-piperidinyl-1'-carboxamide (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 2 OF 8 KAPLUS COPYRIGHT 2004 ACS on STM (Continued)



RD 63712-20-0 KAPLUS  
Benzamide acid, 4-[[[12a-1-[(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-oxo-3,4-dihydroquinolin-2-yl)-piperidin-3-onyl]-4'-piperidinyl]-4'-piperidinyl]-4'-piperidinyl]-1'-carboxamide (CN INDEX NAME)

Absolute stereochemistry.




RD 63712-22-0 KAPLUS  
CN Draw. N-[[12a-1-[(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-oxo-3,4-dihydroquinolin-2-yl)-piperidin-3-onyl]-4'-piperidinyl]-4'-piperidinyl]-4'-piperidinyl-1'-carboxamide (CN INDEX NAME)

Absolute stereochemistry.




11 / ARTICLE 2 OF 8 HOMPLUS COPYRIGHT 2018 ACS on STM (CONTINUED)



615712-11-1 NCAAPLEN  
Urea, N-[1155-1-(11,4'-bipiperidin-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-methyl-2H-quinazolin-2-yl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



**PM** 638712-12-2 NCAPLAW  
**CM** Urea, N-[[[4-(1-{3,6'-bipiperidin-1'-ylcarbonyl}-3-{4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl}-3-scopropyl)-N'-(4-bromo-2-methylphenyl)-


Absolute stereochemistry.

317 ANSWER 2 OF 4 NCAPUS COPYRIGHT 2016 ACS on STN (Continued)



NN 638712-39-6 K0AG1L5  
 CN Urea, N-[1,1'-biphenyl]-2-yl-N'-[1,4-bis(4'-bipiperidin-1-yl-carbonyl)-3-{4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl}-(CA INDEX NAME)


Absolute stereochemistry.



CS 635712-38-8 NCAFLTS  
Urea, N-[[[1,4-bis(4'-bipiperidin-2'-ylcarbonyl)-3-[[4-(2,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethylmethoxyethyl)urea]]-N-CA THREE NAME]


Analytical stereochemistry.

137 ANSWER 2 OF 6 INCAPABLE COPYRIGHT 2009 ACS on STM (06619440)




**IN** 615712-32-3 HCAPLOS  
**CS** Urea, N-[1-[5-(1-[(1,4'-bipiperidin)-1'-yl-carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-cycpropyl)-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)

### Absolute stereochemistry.



**IN** 615712-34-4 NCAPL00  
**CS** Benzoic acid, 3-[[[(1S)-1-[(11,4'-bis(piperidin-1'-ylcarboxyl)-3-[6-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-2-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)  
 Absolute stereochemistry.

117 ANSWER 2 OF 8 BODMAS COPYRIGHT 2000 ACS on 5TH (Cont:Lead)



[illegible]

## 3377 ASSOCIATION OF ORAL INFLAMMATION, COPYRIGHT 2018 ACS, ON SITE (CONTINUED)

615/12-10-09 615/12-31-10 615/12-32-20  
615/12-33-30 615/12-34-40 615/12-35-50  
615/12-36-00  
RL: DAC (Pharmacological activity); SPH (Synthetic preparation); THU  
(Therapeutic use); BHL (Biological study); PREP (Preparation); USRE  
(Uses)

```




```

```

CN      urea, N-[ (1S)-1-[(1S)-1'-bipiperidin]-1'-ylcarbonyl]-3-[4-(2,4-dihydro-2-oxo-
      3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalsyl)- (CA
      UNLX: 0404K)

```

### Absolute stereochemistry




808 634 711-72-2 NCARLEYS

```

C01  Urea, N-[[1-[1-(1-(1,4'-bipiperidin)-5'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-
INDEX NAME)

```

### Absolute stereochemistry



NS 638 711-73-8 HCAFLWS


```

001  Urea, N-[[[1-(1,4-bis(2,6-dimethyl-4-oxo-1,2,3,4-tetrahydropyridin-3-yl)-1H-pyridin-2-yl)-1H-pyridin-2-yl]-
002  1-yl]-N'-[4-(2,4-dihydro-2-oxo-3(1H)-quinazolinyl)-1-piperidinyl]-3-cyclopropyl]-N"-1-naphthalenyl]- (CA
003  INDEX NAME)

```

### Absolute stereochemistry


3.17. ASSANGE, S. OR F. INCREASED COPYRIGHT 2009 ACS. OR. 31N. (00461044-0)



635713-75-9 HCAFLUC

CH Urea, N-[1-(1R)-1-[(1,4,4-tripiperidin)-1'-yl-carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalonyl)-1-piperidinyl]-3-oxopropyl]-N'-[2,4,5-trimethylphenyl]- (CA [REDACTED])

#### Absolute stereochemistry.




800 625-711-76-1 HCAPLUG

03 Urea, N-[1-[1-[1-(1,4-bis(piperidin-3-yl)carbonyl)-2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-5-piperidinyl]-3-oxopropyl]-N'-[4-chloropropyl]- (CA  
[SEE NAME]

### Absolute Stereochemistry


11T ANSWER 5 OF 8 INCAPABLE COPYRIGHT 2016 ACS on 5TH (Continued)



NS 638711-77-2 HCA7L45

Urea, N-[1-[4-(1-{[1,4'-bipiperidin-2'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)

### Absolute stereochemistry




706 639 722-78-3 HCAPILOS

Urea, N-[1-[4-(1-(1,4'-bipiperidin-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-H'-(2-ethylphenyl)- (CA INDEX NAME)

## Absolute stereochemistry


## 117 ANSWER 5 OF 8: BODMAS. COPYRIGHT 2008 ACS on 5TH (Continued)



NO 635711-79-8 HCAFLUS

CS Urea, N-[1-[1-(1-(1,4'-bipiperidin)-1'-ylcarbonyl)-2-[4-(2,4-dihydro-2-oxo-3(1H)-quinazolinyl)-1-piperidinyl]-3-isopropyl]-N'-phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



838 625711-80-7 HCARLOS

CE Urea, N-[1,1'-biphenyl]-4-yl-N'-[18]-1-(1,1'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-diazepa-2-one-2(1H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)- (CA INDEX NAME)


### Absolute stereochemistry



117 ANSWER 5 OF 8 ROUNDS: COPYRIGHT 2008 ACS on STM (Continued)


RD 635711-42-0 ROUNDS  
CN Dose: W-[11b-1-(11,8'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-3-oxo-3H-quinoxalin-6-yl)-piperidinyl]-3-methyl-4H-(1,4-benzoxaphenyl)]- (CN INDEX NAME)

Absolute stereochemistry.



RD 635711-42-0 ROUNDS  
CN Dose: W-[11b-1-(11,8'-bipiperidin-3'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3H-quinoxalin-6-yl)-piperidinyl]-3-methyl-4H-(1,4-benzoxaphenyl)]- (CN INDEX NAME)

Absolute stereochemistry.




RD 635711-44-0 ROUNDS  
CN Dose: W-[11b-1-(11,8'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-3-oxo-3H-quinoxalin-6-yl)-piperidinyl]-3-methyl-4H-(1,4-benzoxaphenyl)]- (CN INDEX NAME)

Absolute stereochemistry.




117 ANSWER 5 OF 8 ROUNDS: COPYRIGHT 2008 ACS on STM (Continued)



RD 635711-44-0 ROUNDS  
CN Dose: W-[11b-1-(11,8'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-3-oxo-3H-quinoxalin-6-yl)-piperidinyl]-3-methyl-4H-(1,4-benzoxaphenyl)]- (CN INDEX NAME)

Absolute stereochemistry.



RD 635711-44-0 ROUNDS  
CN Dose: W-[11b-1-(11,8'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-3-oxo-3H-quinoxalin-6-yl)-piperidinyl]-3-methyl-4H-(1,4-benzoxaphenyl)]- (CN INDEX NAME)


Absolute stereochemistry.



117 ANSWER 5 OF 8 ROUNDS: COPYRIGHT 2008 ACS on STM (Continued)


RD 635711-46-0 ROUNDS  
CN Dose: W-[11b-1-(11,8'-bipiperidin-3'-ylcarbonyl)-3-[4-(1,4-dihydro-3-oxo-3H-quinoxalin-6-yl)-piperidinyl]-3-methyl-4H-(1,4-benzoxaphenyl)]- (CN INDEX NAME)

Absolute stereochemistry.



RD 635711-46-0 ROUNDS  
CN Dose: W-[11b-1-(11,8'-bipiperidin-3'-ylcarbonyl)-3-[4-(1,4-dihydro-3-oxo-3H-quinoxalin-6-yl)-piperidinyl]-3-methyl-4H-(1,4-benzoxaphenyl)]- (CN INDEX NAME)

Absolute stereochemistry.




RD 635711-46-0 ROUNDS  
CN Dose: W-[11b-1-(11,8'-bipiperidin-3'-ylcarbonyl)-3-[4-(1,4-dihydro-3-oxo-3H-quinoxalin-6-yl)-piperidinyl]-3-methyl-4H-(1,4-benzoxaphenyl)]- (CN INDEX NAME)

Absolute stereochemistry.




117 ANSWER 5 OF 8 ROUNDS: COPYRIGHT 2008 ACS on STM (Continued)



RD 635711-46-0 ROUNDS  
CN Dose: W-[11b-1-(11,8'-bipiperidin-3'-ylcarbonyl)-3-[4-(1,4-dihydro-3-oxo-3H-quinoxalin-6-yl)-piperidinyl]-3-methyl-4H-(1,4-benzoxaphenyl)]- (CN INDEX NAME)

Absolute stereochemistry.




RD 635711-47-0 ROUNDS  
CN Dose: W-[11b-1-(11,8'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-3-oxo-3H-quinoxalin-6-yl)-piperidinyl]-3-methyl-4H-(1,4-benzoxaphenyl)]- (CN INDEX NAME)

Absolute stereochemistry.




117 ANSWER 5 OF 8 KOPALUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635711-62-3 KOPALUS  
 CD Urea, N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalyl)]-5-piperidinyl]-3-methyl-4'-[2,4,6-trimethylphenyl]- (CA INDEX NAME)


Absolute stereochemistry



RD 635711-63-3 KOPALUS  
 CD Urea, N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalyl)]-5-piperidinyl]-4'-[2,4,6-trifluorophenyl]- (CA INDEX NAME)


Absolute stereochemistry

117 ANSWER 5 OF 8 KOPALUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635711-64-3 KOPALUS  
 CD Urea, N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalyl)]-5-piperidinyl]-3-methyl-4'-[2,4,6-trimethylphenyl]- (CA INDEX NAME)


Absolute stereochemistry



RD 635711-65-3 KOPALUS  
 CD Urea, N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalyl)]-5-piperidinyl]-3-methyl-4'-[2,4,6-trimethylphenyl]- (CA INDEX NAME)


Absolute stereochemistry

117 ANSWER 5 OF 8 KOPALUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635711-66-3 KOPALUS  
 CD Urea, N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalyl)]-5-piperidinyl]-3-methyl-4'-[2,4,6-trimethylphenyl]- (CA INDEX NAME)


Absolute stereochemistry



RD 635711-67-3 KOPALUS  
 CD Urea, N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalyl)]-5-piperidinyl]-3-methyl-4'-[2,4,6-trimethylphenyl]- (CA INDEX NAME)


Absolute stereochemistry

117 ANSWER 5 OF 8 KOPALUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635711-68-3 KOPALUS  
 CD Urea, N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalyl)]-5-piperidinyl]-3-methyl-4'-[2,4,6-trimethylphenyl]- (CA INDEX NAME)


Absolute stereochemistry



RD 635711-69-3 KOPALUS  
 CD Urea, N-[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalyl)]-5-piperidinyl]-3-methyl-4'-[2,4,6-trimethylphenyl]- (CA INDEX NAME)


Absolute stereochemistry

117 ANSWER 5 OF 8 KOMPAS COPYRIGHT 2008 ACS on STM (Continued)



RN 63712-62-4 KOMPAS  
CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)methyl]-3-[(4-(1,4-dihydro-2-oxo-3(1H)-quinoxalin-1-yl)-5-pyridinyl)-3-propenyl]-4H-(1,2,4-triazol-5-yl)]-4-phenyl-1H-pyrazol-5-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 63712-62-5 KOMPAS  
CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)methyl]-3-[(4-(1,4-dihydro-2-oxo-3(1H)-quinoxalin-1-yl)-5-pyridinyl)-3-propenyl]-4H-(1,2,4-triazol-5-yl)]-4-(2-fluorophenyl)-1H-pyrazol-5-yl- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 KOMPAS COPYRIGHT 2008 ACS on STM (Continued)



RN 63712-62-6 KOMPAS  
CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)methyl]-3-[(4-(1,4-dihydro-2-oxo-3(1H)-quinoxalin-1-yl)-5-pyridinyl)-3-propenyl]-4H-(1,2,4-triazol-5-yl)]-4-(2,6-dichlorophenyl)-1H-pyrazol-5-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 63712-64-8 KOMPAS  
CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)methyl]-3-[(4-(1,4-dihydro-2-oxo-3(1H)-quinoxalin-1-yl)-5-pyridinyl)-3-propenyl]-4H-(1,2,4-triazol-5-yl)]-4-(2-phenyl-5-thienylphenyl)-1H-pyrazol-5-yl- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 KOMPAS COPYRIGHT 2008 ACS on STM (Continued)



RN 63712-68-9 KOMPAS  
CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)methyl]-3-[(4-(1,4-dihydro-2-oxo-3(1H)-quinoxalin-1-yl)-5-pyridinyl)-3-propenyl]-4H-(1,2,4-triazol-5-yl)]-4-(2-(4-chlorophenyl)-5-thienylphenyl)-1H-pyrazol-5-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 63712-69-2 KOMPAS  
CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)methyl]-3-[(4-(1,4-dihydro-2-oxo-3(1H)-quinoxalin-1-yl)-5-pyridinyl)-3-propenyl]-4H-(1,2,4-triazol-5-yl)]-4-(2,4-difluorophenyl)-1H-pyrazol-5-yl- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 KOMPAS COPYRIGHT 2008 ACS on STM (Continued)



RN 63712-69-3 KOMPAS  
CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)methyl]-3-[(4-(1,4-dihydro-2-oxo-3(1H)-quinoxalin-1-yl)-5-pyridinyl)-3-propenyl]-4H-(1,2,4-triazol-5-yl)]-4-(2-phenyl-5-(4-chlorophenyl)phenyl)-1H-pyrazol-5-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 63712-69-4 KOMPAS  
CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)methyl]-3-[(4-(1,4-dihydro-2-oxo-3(1H)-quinoxalin-1-yl)-5-pyridinyl)-3-propenyl]-4H-(1,2,4-triazol-5-yl)]-4-(2-chlorophenyl)-1H-pyrazol-5-yl- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 NCMPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-11-3 NCMPLUS  
 CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-(4-(1,4-dihydro-2-oxo-3-(2-oxo-1H-imidazol-1-yl)-3-piperidinyl)-3-propenyl)-4'-chlorophenyl]- (CN INDEX NAME)


Absolute stereochemistry.



RD 63712-12-0 NCMPLUS  
 CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-(4-(1,4-dihydro-2-oxo-3-(2-oxo-1H-imidazol-1-yl)-3-piperidinyl)-3-propenyl)-4'-hydroxyphenyl]- (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 NCMPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-13-9 NCMPLUS  
 CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-(4-(1,4-dihydro-2-oxo-3-(2-oxo-1H-imidazol-1-yl)-3-piperidinyl)-3-propenyl)-4'-bromophenyl]- (CN INDEX NAME)


Absolute stereochemistry.



RD 63712-14-0 NCMPLUS  
 CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-(4-(1,4-dihydro-2-oxo-3-(2-oxo-1H-imidazol-1-yl)-3-piperidinyl)-3-propenyl)-4'-fluorophenyl]- (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 NCMPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-15-1 NCMPLUS  
 CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-(4-(1,4-dihydro-2-oxo-3-(2-oxo-1H-imidazol-1-yl)-3-piperidinyl)-3-propenyl)-4'-fluorophenyl]- (CN INDEX NAME)


Absolute stereochemistry.



RD 63712-16-2 NCMPLUS  
 CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-(4-(1,4-dihydro-2-oxo-3-(2-oxo-1H-imidazol-1-yl)-3-piperidinyl)-3-propenyl)-4'-chlorophenyl]- (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 NCMPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-17-3 NCMPLUS  
 CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-(4-(1,4-dihydro-2-oxo-3-(2-oxo-1H-imidazol-1-yl)-3-piperidinyl)-3-propenyl)-4'-bromophenyl]- (CN INDEX NAME)


Absolute stereochemistry.



RD 63712-18-0 NCMPLUS  
 CN Drex. N-[(1R)-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-(4-(1,4-dihydro-2-oxo-3-(2-oxo-1H-imidazol-1-yl)-3-piperidinyl)-3-propenyl)-4'-methoxyphenyl]- (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 R04PUSU COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-22-8 R04PUSU  
 CN Drev. N-[(1S)-1-[(1,4'-bipiperidin-3'-yl)oxomethyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-piperidin-3-yl]-N-methyl-N-methyl-2-oxoethan-1-amine]-N-methyl-2-oxoethan-1-amine] (CA INDEX NAME)


Absolute stereochemistry.



RD 63712-23-0 R04PUSU  
 CN Drev. N-[(1S)-1-[(1,4'-bipiperidin-3'-yl)oxomethyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-piperidin-3-yl]-N-methyl-N-methyl-2-oxoethan-1-amine]-N-methyl-2-oxoethan-1-amine] (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 R04PUSU COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-23-1 R04PUSU  
 CN Drev. N-[(1S)-1-[(1,4'-bipiperidin-3'-yl)oxomethyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-piperidin-3-yl]-N-methyl-N-methyl-2-oxoethan-1-amine]-N-methyl-2-oxoethan-1-amine] (CA INDEX NAME)


Absolute stereochemistry.



RD 63712-24-5 R04PUSU  
 CN Drev. N-[(1S)-1-[(1,4'-bipiperidin-3'-yl)oxomethyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-piperidin-3-yl]-N-methyl-N-methyl-2-oxoethan-1-amine]-N-methyl-2-oxoethan-1-amine] (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 R04PUSU COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-25-3 R04PUSU  
 CN Drev. N-[(1S)-1-[(1,4'-bipiperidin-3'-yl)oxomethyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-piperidin-3-yl]-N-methyl-N-methyl-2-oxoethan-1-amine]-N-methyl-2-oxoethan-1-amine] (CA INDEX NAME)


Absolute stereochemistry.



RD 63712-26-4 R04PUSU  
 CN Drev. N-[(1S)-1-[(1,4'-bipiperidin-3'-yl)oxomethyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-piperidin-3-yl]-N-methyl-N-methyl-2-oxoethan-1-amine]-N-methyl-2-oxoethan-1-amine] (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 R04PUSU COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-27-8 R04PUSU  
 CN Drev. N-[(1S)-1-[(1,4'-bipiperidin-3'-yl)oxomethyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-piperidin-3-yl]-N-methyl-N-methyl-2-oxoethan-1-amine]-N-methyl-2-oxoethan-1-amine] (CA INDEX NAME)


Absolute stereochemistry.



RD 63712-28-4 R04PUSU  
 CN Drev. N-[(1S)-1-[(1,4'-bipiperidin-3'-yl)oxomethyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-piperidin-3-yl]-N-methyl-N-methyl-2-oxoethan-1-amine]-N-methyl-2-oxoethan-1-amine] (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 5 OF 8 NOAPLUS COPYRIGHT 2008 ACS on B3H (Continued)



RD 637112-16-3 NOAPLUS  
 CN O=Cc1cc(C(=O)N[C@@H](C2CCNCC2)C(=O)N[C@@H](C3CCNCC3)C(=O)Nc4cc5ccccc5cc4)ccc1N


Absolute stereochemistry.



RD 637112-16-0 NOAPLUS  
 CN O=Cc1cc(C(=O)N[C@@H](C2CCNCC2)C(=O)N[C@@H](C3CCNCC3)C(=O)Nc4cc5ccccc5cc4)ccc1N


Absolute stereochemistry.

117 ANSWER 5 OF 8 NOAPLUS COPYRIGHT 2008 ACS on B3H (Continued)



RD 637112-31-1 NOAPLUS  
 CN O=Cc1cc(C(=O)N[C@@H](C2CCNCC2)C(=O)N[C@@H](C3CCNCC3)C(=O)Nc4cc5ccccc5cc4)ccc1N


Absolute stereochemistry.



RD 637112-31-0 NOAPLUS  
 CN O=Cc1cc(C(=O)N[C@@H](C2CCNCC2)C(=O)N[C@@H](C3CCNCC3)C(=O)Nc4cc5ccccc5cc4)ccc1N


Absolute stereochemistry.

117 ANSWER 5 OF 8 NOAPLUS COPYRIGHT 2008 ACS on B3H (Continued)



RD 637112-33-0 NOAPLUS  
 CN O=Cc1cc(C(=O)N[C@@H](C2CCNCC2)C(=O)N[C@@H](C3CCNCC3)C(=O)Nc4cc5ccccc5cc4)ccc1N


Absolute stereochemistry.



RD 637112-36-1 NOAPLUS  
 CN O=Cc1cc(C(=O)N[C@@H](C2CCNCC2)C(=O)N[C@@H](C3CCNCC3)C(=O)Nc4cc5ccccc5cc4)ccc1N


Absolute stereochemistry.

117 ANSWER 5 OF 8 NOAPLUS COPYRIGHT 2008 ACS on B3H (Continued)



RD 637112-38-0 NOAPLUS  
 CN O=Cc1cc(C(=O)N[C@@H](C2CCNCC2)C(=O)N[C@@H](C3CCNCC3)C(=O)Nc4cc5ccccc5cc4)ccc1N

Absolute stereochemistry.




RD 637112-38-1 NOAPLUS  
 CN O=Cc1cc(C(=O)N[C@@H](C2CCNCC2)C(=O)N[C@@H](C3CCNCC3)C(=O)Nc4cc5ccccc5cc4)ccc1N

Absolute stereochemistry.

FIG. 1072 1

THESE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE-ENT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

[illegible]


The title compound, **1** (**Cy**) represents an optimally substituted aromatic heterocyclic group as represented by optimally substituted aromatic heterocyclic groups R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, R<sub>14</sub>, R<sub>15</sub>, R<sub>16</sub>, R<sub>17</sub>, R<sub>18</sub>, R<sub>19</sub>, R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub>, R<sub>24</sub>, R<sub>25</sub>, R<sub>26</sub>, R<sub>27</sub>, R<sub>28</sub>, R<sub>29</sub>, R<sub>30</sub>, R<sub>31</sub>, R<sub>32</sub>, R<sub>33</sub>, R<sub>34</sub>, R<sub>35</sub>, R<sub>36</sub>, R<sub>37</sub>, R<sub>38</sub>, R<sub>39</sub>, R<sub>40</sub>, R<sub>41</sub>, R<sub>42</sub>, R<sub>43</sub>, R<sub>44</sub>, R<sub>45</sub>, R<sub>46</sub>, R<sub>47</sub>, R<sub>48</sub>, R<sub>49</sub>, R<sub>50</sub>, R<sub>51</sub>, R<sub>52</sub>, R<sub>53</sub>, R<sub>54</sub>, R<sub>55</sub>, R<sub>56</sub>, R<sub>57</sub>, R<sub>58</sub>, R<sub>59</sub>, R<sub>60</sub>, R<sub>61</sub>, R<sub>62</sub>, R<sub>63</sub>, R<sub>64</sub>, R<sub>65</sub>, R<sub>66</sub>, R<sub>67</sub>, R<sub>68</sub>, R<sub>69</sub>, R<sub>70</sub>, R<sub>71</sub>, R<sub>72</sub>, R<sub>73</sub>, R<sub>74</sub>, R<sub>75</sub>, R<sub>76</sub>, R<sub>77</sub>, R<sub>78</sub>, R<sub>79</sub>, R<sub>80</sub>, R<sub>81</sub>, R<sub>82</sub>, R<sub>83</sub>, R<sub>84</sub>, R<sub>85</sub>, R<sub>86</sub>, R<sub>87</sub>, R<sub>88</sub>, R<sub>89</sub>, R<sub>90</sub>, R<sub>91</sub>, R<sub>92</sub>, R<sub>93</sub>, R<sub>94</sub>, R<sub>95</sub>, R<sub>96</sub>, R<sub>97</sub>, R<sub>98</sub>, R<sub>99</sub>, R<sub>100</sub>, R<sub>101</sub>, R<sub>102</sub>, R<sub>103</sub>, R<sub>104</sub>, R<sub>105</sub>, R<sub>106</sub>, R<sub>107</sub>, R<sub>108</sub>, R<sub>109</sub>, R<sub>110</sub>, R<sub>111</sub>, R<sub>112</sub>, R<sub>113</sub>, R<sub>114</sub>, R<sub>115</sub>, R<sub>116</sub>, R<sub>117</sub>, R<sub>118</sub>, R<sub>119</sub>, R<sub>120</sub>, R<sub>121</sub>, R<sub>122</sub>, R<sub>123</sub>, R<sub>124</sub>, R<sub>125</sub>, R<sub>126</sub>, R<sub>127</sub>, R<sub>128</sub>, R<sub>129</sub>, R<sub>130</sub>, R<sub>131</sub>, R<sub>132</sub>, R<sub>133</sub>, R<sub>134</sub>, R<sub>135</sub>, R<sub>136</sub>, R<sub>137</sub>, R<sub>138</sub>, R<sub>139</sub>, R<sub>140</sub>, R<sub>141</sub>, R<sub>142</sub>, R<sub>143</sub>, R<sub>144</sub>, R<sub>145</sub>, R<sub>146</sub>, R<sub>147</sub>, R<sub>148</sub>, R<sub>149</sub>, R<sub>150</sub>, R<sub>151</sub>, R<sub>152</sub>, R<sub>153</sub>, R<sub>154</sub>, R<sub>155</sub>, R<sub>156</sub>, R<sub>157</sub>, R<sub>158</sub>, R<sub>159</sub>, R<sub>160</sub>, R<sub>161</sub>, R<sub>162</sub>, R<sub>163</sub>, R<sub>164</sub>, R<sub>165</sub>, R<sub>166</sub>, R<sub>167</sub>, R<sub>168</sub>, R<sub>169</sub>, R<sub>170</sub>, R<sub>171</sub>, R<sub>172</sub>, R<sub>173</sub>, R<sub>174</sub>, R<sub>175</sub>, R<sub>176</sub>, R<sub>177</sub>, R<sub>178</sub>, R<sub>179</sub>, R<sub>180</sub>, R<sub>181</sub>, R<sub>182</sub>, R<sub>183</sub>, R<sub>184</sub>, R<sub>185</sub>, R<sub>186</sub>, R<sub>187</sub>, R<sub>188</sub>, R<sub>189</sub>, R<sub>190</sub>, R<sub>191</sub>, R<sub>192</sub>, R<sub>193</sub>, R<sub>194</sub>, R<sub>195</sub>, R<sub>196</sub>, R<sub>197</sub>, R<sub>198</sub>, R<sub>199</sub>, R<sub>200</sub>, R<sub>201</sub>, R<sub>202</sub>, R<sub>203</sub>, R<sub>204</sub>, R<sub>205</sub>, R<sub>206</sub>, R<sub>207</sub>, R<sub>208</sub>, R<sub>209</sub>, R<sub>210</sub>, R<sub>211</sub>, R<sub>212</sub>, R<sub>213</sub>, R<sub>214</sub>, R<sub>215</sub>, R<sub>216</sub>, R<sub>217</sub>, R<sub>218</sub>, R<sub>219</sub>, R<sub>220</sub>, R<sub>221</sub>, R<sub>222</sub>, R<sub>223</sub>, R<sub>224</sub>, R<sub>225</sub>, R<sub>226</sub>, R<sub>227</sub>, R<sub>228</sub>, R<sub>229</sub>, R<sub>230</sub>, R<sub>231</sub>, R<sub>232</sub>, R<sub>233</sub>, R<sub>234</sub>, R<sub>235</sub>, R<sub>236</sub>, R<sub>237</sub>, R<sub>238</sub>, R<sub>239</sub>, R<sub>240</sub>, R<sub>241</sub>, R<sub>242</sub>, R<sub>243</sub>, R<sub>244</sub>, R<sub>245</sub>, R<sub>246</sub>, R<sub>247</sub>, R<sub>248</sub>, R<sub>249</sub>, R<sub>250</sub>, R<sub>251</sub>, R<sub>252</sub>, R<sub>253</sub>, R<sub>254</sub>, R<sub>255</sub>, R<sub>256</sub>, R<sub>257</sub>, R<sub>258</sub>, R<sub>259</sub>, R<sub>260</sub>, R<sub>261</sub>, R<sub>262</sub>, R<sub>263</sub>, R<sub>264</sub>, R<sub>265</sub>, R<sub>266</sub>, R<sub>267</sub>, R<sub>268</sub>, R<sub>269</sub>, R<sub>270</sub>, R<sub>271</sub>, R<sub>272</sub>, R<sub>273</sub>, R<sub>274</sub>, R<sub>275</sub>, R<sub>276</sub>, R<sub>277</sub>, R<sub>278</sub>, R<sub>279</sub>, R<sub>280</sub>, R<sub>281</sub>, R<sub>282</sub>, R<sub>283</sub>, R<sub>284</sub>, R<sub>285</sub>, R<sub>286</sub>, R<sub>287</sub>, R<sub>288</sub>, R<sub>289</sub>, R<sub>290</sub>, R<sub>291</sub>, R<sub>292</sub>, R<sub>293</sub>, R<sub>294</sub>, R<sub>295</sub>, R<sub>296</sub>, R<sub>297</sub>, R<sub>298</sub>, R<sub>299</sub>, R<sub>300</sub>, R<sub>301</sub>, R<sub>302</sub>, R<sub>303</sub>, R<sub>304</sub>, R<sub>305</sub>, R<sub>306</sub>, R<sub>307</sub>, R<sub>308</sub>, R<sub>309</sub>, R<sub>310</sub>, R<sub>311</sub>, R<sub>312</sub>, R<sub>313</sub>, R<sub>314</sub>, R<sub>315</sub>, R<sub>316</sub>, R<sub>317</sub>, R<sub>318</sub>, R<sub>319</sub>, R<sub>320</sub>, R<sub>321</sub>, R<sub>322</sub>, R<sub>323</sub>, R<sub>324</sub>, R<sub>325</sub>, R<sub>326</sub>, R<sub>327</sub>, R<sub>328</sub>, R<sub>329</sub>, R<sub>330</sub>, R<sub>331</sub>, R<sub>332</sub>, R<sub>333</sub>, R<sub>334</sub>, R<sub>335</sub>, R<sub>336</sub>, R<sub>337</sub>, R<sub>338</sub>, R<sub>339</sub>, R<sub>340</sub>, R<sub>341</sub>, R<sub>342</sub>, R<sub>343</sub>, R<sub>344</sub>, R<sub>345</sub>, R<sub>346</sub>, R<sub>347</sub>, R<sub>348</sub>, R<sub>349</sub>, R<sub>350</sub>, R<sub>351</sub>, R<sub>352</sub>, R<sub>353</sub>, R<sub>354</sub>, R<sub>355</sub>, R<sub>356</sub>, R<sub>357</sub>, R<sub>358</sub>, R<sub>359</sub>, R<sub>360</sub>, R<sub>361</sub>, R<sub>362</sub>, R<sub>363</sub>, R<sub>364</sub>, R<sub>365</sub>, R<sub>366</sub>, R<sub>367</sub>, R<sub>368</sub>, R<sub>369</sub>, R<sub>370</sub>, R<sub>371</sub>, R<sub>372</sub>, R<sub>373</sub>, R<sub>374</sub>, R<sub>375</sub>, R<sub>376</sub>, R<sub>377</sub>, R<sub>378</sub>, R<sub>379</sub>, R<sub>380</sub>, R<sub>381</sub>, R<sub>382</sub>, R<sub>383</sub>, R<sub>384</sub>, R<sub>385</sub>, R<sub>386</sub>, R<sub>387</sub>, R<sub>388</sub>, R<sub>389</sub>, R<sub>390</sub>, R<sub>391</sub>, R<sub>392</sub>, R<sub>393</sub>, R<sub>394</sub>, R<sub>395</sub>, R<sub>396</sub>, R<sub>397</sub>, R<sub>398</sub>, R<sub>399</sub>, R<sub>400</sub>, R<sub>401</sub>, R<sub>402</sub>, R<sub>403</sub>, R<sub>404</sub>, R<sub>405</sub>, R<sub>406</sub>, R<sub>407</sub>, R<sub>408</sub>, R<sub>409</sub>, R<sub>410</sub>, R<sub>411</sub>, R<sub>412</sub>, R<sub>413</sub>, R<sub>414</sub>, R<sub>415</sub>, R<sub>416</sub>, R

Absolute stereochemistry:

O=C(C[C@@H](C1=CC=C(C=C1)Cl)C(=O)N[C@H]2CCN(C2)C(=O)N)C(=O)N[C@H]3CCN(C3)C(=O)N

CC1=CC=C(C=C1)C(=O)N[C@@H](C(=O)N[C@H]2CCN(C2)C(=O)N)C(=O)N[C@H]3CCN(C3)C(=O)N


RE CNT 49 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD

[illegible][illegible]






## 11 / ANSWER 7 OF 8 HOMPLUS COPYRIGHT 2009 ACS on STM (CONTINUED)



**NAME** 615711-81-0 NEAPLOW  
**SYN** Urea, N-[1(1S)-1-(1-{[4'-bis(piperidin-1-yl-carbonyl)-3-{4-(1,4-dihydro-2-soxo-3(2H)-quinazolinyl)-1-piperidiny]-3-carboxypropyl}-N'-[(1R,2E)-2-(phenylcyclopropyl)]-1-OA)196XK NAAM]


Absolute stereochemistry.



CS Urea, N-(1-[1,4-bis(4-*N*-bipiperidinyl-2-ylcarbonyl)-3-(4-*N*-4-dihydro-2-oxo-3(2*H*)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-*N*-(2, 4-dimethoxyphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.

## 137 AUTHOR: Y OF 6 INCIPIS COPYRIGHT 2009 ACS ON 3TH (C061044G)



30 615711-52-2 HCAPLEN  
 C# Urea, N-[(1S)-1-[(1S,4S)-bicyclopentyl]-3-ylcarbonyl]-3-[4-(1,4-dihydro-3-oxo-3(2H)-quinazolinyl)-2-piperidinyl]-3-oxopropyl]-N'-[2,4-difluorophenyl]-  
 (CA INDEX NAME)


Absolute stereochemistry.



RX 615711-64-3 HCARLOS  
 CH Urea, N-[(1S)-1-[(1,4'-bipiperidin)-2'-ylcarbonyl]-3-[4-(1,4-dihydro-7-oxo-3-(2H)-quinolin-2-yl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-  
 (CA INDEX NAME)


#### Absolute stereochemistry.

## 117 ANSWER T OF 8 HCAPUS COPYRIGHT 2018 ACS on 5/18 (Continued)



Urea, N-[118]-1-(3,4'-bipiperidin)-2'-glycarbonyl]-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3,4-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



```
IN 635711-98-0 HONOLULU
DS Urea; N-[1[(1R)-1-(1,4-dioxo-1H-piperidin-2-yl)carbamoyl]-3-methyl-4-hydroxy-2-oxo-2H-1,2,4-triazolo[4,5-f]pyrimidin-5(1H)-ylideneamino]-N'-methyl-N-chlorosulfonyl-
(2A INDEX NAME)
```


### Appendix 5: References

## 137 ANSWER 7 OF 8 BCBPUBS COPYRIGHT 2008 ACS on STN (Continued)



RX 615711-57-4 HCARLOS  
 CR Urea, N-[(1S)-1-[(1,4'-bipiperidin)-2'-ylcarbonyl]-3-[4-(1,4-dihydro-3-oxo-3(2H)-quinazolinyl)-2-piperidinyl]-3-oxopropyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




```

89  625711-58-7  HOARLOS
90  Wren, W= (135)-1-(1,4'-bis(piperidin)-1'-yl-4-oxobenzyl)-3-(18-c), 4-dihydropyrazolo-2-one-3-(2H)-quinolin-6-yl)-1-piperidin-4-yl)-3-cisocyclopropyl)-N'-2, 4-dichlorophenyl)-(CO, INDEX NAME)

```


ABSOLUTE SCORING: 515V

117 ASSESS 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on BTH (Continued)



RD 635711-10-0 HCAPLUS  
 CN Drev. N=118-1-(1,4'-bipiperidin-1'-yl)-2-(4-cyclohexyl-2-methyl-phenyl)-3-piperidinyl-4-methyl-4-chlorophenyl- (CA INDEX NAME)


Absolute stereochemistry.



RD 635711-11-0 HCAPLUS  
 CN Drev. N=118-1-(1,4'-bipiperidin-1'-yl)-2-(4-cyclohexyl-2-methyl-phenyl)-3-piperidinyl-4-methyl-4-chlorophenyl- (CA INDEX NAME)


Absolute stereochemistry.

117 ASSESS 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on BTH (Continued)



RD 635712-01-0 HCAPLUS  
 CN Drev. N=118-1-(1,4'-bipiperidin-1'-yl)-2-(4-cyclohexyl-2-methyl-phenyl)-3-piperidinyl-4-methyl-4-chlorophenyl- (CA INDEX NAME)


Absolute stereochemistry.



RD 635712-01-0 HCAPLUS  
 CN Drev. N=118-1-(1,4'-bipiperidin-1'-yl)-2-(4-cyclohexyl-2-methyl-phenyl)-3-piperidinyl-4-methyl-4-chlorophenyl- (CA INDEX NAME)


Absolute stereochemistry.

117 ASSESS 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on BTH (Continued)



RD 635712-14-0 HCAPLUS  
 CN Drev. N=118-1-(1,4'-bipiperidin-1'-yl)-2-(4-cyclohexyl-2-methyl-phenyl)-3-piperidinyl-4-methyl-4-chlorophenyl- (CA INDEX NAME)


Absolute stereochemistry.



RD 635712-15-0 HCAPLUS  
 CN Drev. N=118-1-(1,4'-bipiperidin-1'-yl)-2-(4-cyclohexyl-2-methyl-phenyl)-3-piperidinyl-4-methyl-4-chlorophenyl- (CA INDEX NAME)


Absolute stereochemistry.

117 ASSESS 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on BTH (Continued)



RD 635712-16-0 HCAPLUS  
 CN Drev. N=118-1-(1,4'-bipiperidin-1'-yl)-2-(4-cyclohexyl-2-methyl-phenyl)-3-piperidinyl-4-methyl-4-chlorophenyl- (CA INDEX NAME)


Absolute stereochemistry.



RD 635712-16-0 HCAPLUS  
 CN Drev. N=118-1-(1,4'-bipiperidin-1'-yl)-2-(4-cyclohexyl-2-methyl-phenyl)-3-piperidinyl-4-methyl-4-chlorophenyl- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 7 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-10-6 NOVELUS  
CN Drex. N-[(1a)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[(1,4,6-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-5-piperidinyl]-3-methyl-4'-hydroxyphenyl]-4'-hydroxyphenyl- (CA INDEX NAME)


Absolute stereochemistry.



RD 63712-12-8 NOVELUS  
CN Drex. N-[(1a)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[(1,4,6-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-5-piperidinyl]-3-methyl-4'-hydroxyphenyl]-4'-hydroxyphenyl- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 7 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-12-8 NOVELUS  
CN Drex. N-[(1a)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[(1,4,6-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-5-piperidinyl]-3-methyl-4'-hydroxyphenyl]-4'-hydroxyphenyl- (CA INDEX NAME)


Absolute stereochemistry.



RD 63712-12-8 NOVELUS  
CN Drex. N-[(1a)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[(1,4,6-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-5-piperidinyl]-3-methyl-4'-hydroxyphenyl]-4'-hydroxyphenyl- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 7 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-14-0 NOVELUS  
CN Drex. N-[(1a)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[(1,4,6-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-5-piperidinyl]-3-methyl-4'-hydroxyphenyl]-4'-hydroxyphenyl- (CA INDEX NAME)


Absolute stereochemistry.



RD 63712-14-0 NOVELUS  
CN Drex. N-[(1a)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[(1,4,6-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-5-piperidinyl]-3-methyl-4'-hydroxyphenyl]-4'-hydroxyphenyl- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 7 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-14-0 NOVELUS  
CN Drex. N-[(1a)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[(1,4,6-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-5-piperidinyl]-3-methyl-4'-hydroxyphenyl]-4'-hydroxyphenyl- (CA INDEX NAME)


Absolute stereochemistry.



RD 63712-14-0 NOVELUS  
CN Drex. N-[(1a)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[(1,4,6-dihydro-2-oxo-3(2H)-quinoxalin-1'-yl)-5-piperidinyl]-3-methyl-4'-hydroxyphenyl]-4'-hydroxyphenyl- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 7 OF 8 KOMPUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63713-10-5 KOMPUS  
 CN O=C(N[C@@H](C(=O)Nc1ccc(C)cc1)C(=O)Nc2ccc(C)cc2)C3CCNCC3


Absolute stereochemistry.



RD 63713-12-0 KOMPUS  
 CN O=C(N[C@@H](C(=O)Nc1ccc(C)cc1)C(=O)Nc2ccc(C)cc2)C3CCNCC3


Absolute stereochemistry

117 ANSWER 7 OF 8 KOMPUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63713-12-0 KOMPUS  
 CN O=C(N[C@@H](C(=O)Nc1ccc(C)cc1)C(=O)Nc2ccc(C)cc2)C3CCNCC3


Absolute stereochemistry.



RD 63713-13-1 KOMPUS  
 CN O=C(N[C@@H](C(=O)Nc1ccc(C)cc1)C(=O)Nc2ccc(C)cc2)C3CCNCC3


Absolute stereochemistry.

117 ANSWER 7 OF 8 KOMPUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63713-24-0 KOMPUS  
 CN O=C(N[C@@H](C(=O)Nc1ccc(C)cc1)C(=O)Nc2ccc(C)cc2)C3CCNCC3


Absolute stereochemistry.



RD 63713-24-0 KOMPUS  
 CN O=C(N[C@@H](C(=O)Nc1ccc(C)cc1)C(=O)Nc2ccc(C)cc2)C3CCNCC3


Absolute stereochemistry

117 ANSWER 7 OF 8 KOMPUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63713-26-0 KOMPUS  
 CN O=C(N[C@@H](C(=O)Nc1ccc(C)cc1)C(=O)Nc2ccc(C)cc2)C3CCNCC3

Absolute stereochemistry.




RD 63713-27-0 KOMPUS  
 CN O=C(N[C@@H](C(=O)Nc1ccc(C)cc1)C(=O)Nc2ccc(C)cc2)C3CCNCC3

Absolute stereochemistry.






117 ANSWER 8 OF 8 NOAPLUS OPIR01017 2008 ACS on STM (Continued)



RD 639711-70-0 NOAPLUS

CN Dose: W-[145-1-(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-methyl-2H-quinazolin-2-yl)-piperidinyl]-3-methyl-1H-(4,4'-bicyclohexyl)- (CA INDEX NAME)

Absolute stereochemistry.




RD 639711-76-0 NOAPLUS

CN Dose: W-[145-1-(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-methyl-2H-quinazolinyl)-piperidinyl]-4H-(4,4'-bicyclohexyl)- (CA INDEX NAME)

Absolute stereochemistry.


117 ANSWER 8 OF 8 NOAPLUS OPIR01017 2008 ACS on STM (Continued)



RD 639711-78-0 NOAPLUS

CN Dose: W-[145-1-(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-methyl-2H-quinazolinyl)-piperidinyl]-3-methyl-1H-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RD 639711-80-0 NOAPLUS

CN Dose: W-[145-1-(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-methyl-2H-quinazolinyl)-piperidinyl]-3-methyl-1H-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RD 639711-82-0 NOAPLUS

CN Dose: W-[145-1-(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-methyl-2H-quinazolinyl)-piperidinyl]-3-methyl-1H-phenyl- (CA INDEX NAME)

Absolute stereochemistry.


117 ANSWER 8 OF 8 NOAPLUS OPIR01017 2008 ACS on STM (Continued)



RD 639711-72-0 NOAPLUS

CN Dose: W-[145-1-(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-methyl-2H-quinazolinyl)-piperidinyl]-3-methyl-1H-(4,4'-bicyclohexyl)- (CA INDEX NAME)

Absolute stereochemistry.




RD 639711-76-0 NOAPLUS

CN Dose: W-[145-1-(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-methyl-2H-quinazolinyl)-piperidinyl]-3-methyl-1H-(4,4'-bicyclohexyl)- (CA INDEX NAME)

Absolute stereochemistry.


117 ANSWER 8 OF 8 NOAPLUS OPIR01017 2008 ACS on STM (Continued)



RD 639711-80-0 NOAPLUS

CN Dose: W-[145-1-(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-methyl-2H-quinazolinyl)-piperidinyl]-3-methyl-1H-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RD 639711-82-0 NOAPLUS

CN Dose: W-[145-1-(1,4'-bipiperidin-1'-yl)acetyl]-3-[4-(1,4-dihydro-2-methyl-2H-quinazolinyl)-piperidinyl]-3-methyl-1H-(4,4'-bicyclohexyl)- (CA INDEX NAME)


Absolute stereochemistry.

117 ANSWER 4 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-44-3 NOVELUS  
 CN Draw: N-((1S)-1-((1,4'-bipiperidin-1'-yl-carbonyl)-3-((4-(2,4-dihydro-3-methyl-quinazolin-2-yl)-piperidin-3-onyl)-4'-((2-methylphenyl))- (CN INDEX NAME)


Absolute stereochemistry.



RD 63711-47-4 NOVELUS  
 CN Draw: N-((1S)-1-((1,4'-bipiperidin-1'-yl-carbonyl)-3-((4-(2,4-dihydro-3-methyl-quinazolin-2-yl)-piperidin-3-onyl)-4'-((2-methylphenyl))- (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 4 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-48-5 NOVELUS  
 CN Draw: N-((1S)-1-((1,4'-bipiperidin-1'-yl-carbonyl)-3-((4-(2,4-dihydro-3-methyl-quinazolin-2-yl)-piperidin-3-onyl)-4'-((2,4-dimethylphenyl))- (CN INDEX NAME)


Absolute stereochemistry.



RD 63711-49-6 NOVELUS  
 CN Draw: N-((1S)-1-((1,4'-bipiperidin-1'-yl-carbonyl)-3-((4-(2,4-dihydro-3-methyl-quinazolin-2-yl)-piperidin-3-onyl)-4'-((2,4-dimethylphenyl))- (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 4 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63711-45-1 NOVELUS  
 CN Draw: N-((1S)-1-((1,4'-bipiperidin-1'-yl-carbonyl)-3-((4-(2,4-dihydro-3-methyl-quinazolin-2-yl)-piperidin-3-onyl)-4'-((2-methylphenyl))- (CN INDEX NAME)


Absolute stereochemistry.



RD 63711-46-2 NOVELUS  
 CN Draw: N-((1S)-1-((1,4'-bipiperidin-1'-yl-carbonyl)-3-((4-(2,4-dihydro-3-methyl-quinazolin-2-yl)-piperidin-3-onyl)-4'-((2,4-dimethylphenyl))- (CN INDEX NAME)


Absolute stereochemistry.

117 ANSWER 4 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)




RD 63711-42-1 NOVELUS  
 CN Draw: N-((1S)-1-((1,4'-bipiperidin-1'-yl-carbonyl)-3-((4-(2,4-dihydro-3-methyl-quinazolin-2-yl)-piperidin-3-onyl)-4'-((2,4-dimethylphenyl))- (CN INDEX NAME)

Absolute stereochemistry.



RD 63711-43-2 NOVELUS  
 CN Draw: N-((1S)-1-((1,4'-bipiperidin-1'-yl-carbonyl)-3-((4-(2,4-dihydro-3-methyl-quinazolin-2-yl)-piperidin-3-onyl)-4'-((2,4-dimethylphenyl))- (CN INDEX NAME)


Absolute stereochemistry.



117 ASSEMBY 8 OF 8 NCMPUS COPYRIGHT 2008 ACS on STM (Continued)


NO 639711-61-3 NCMPUS  
OR Dose: N-[118]-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-oxopropyl-N'-[2,6-dimethylphenyl]- (CA INDEX NAME)

Absolute stereochemistry.



NO 639711-61-4 NCMPUS  
OR Dose: N-[118]-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-oxopropyl-N'-[2,6-dimethylphenyl]- (CA INDEX NAME)


Absolute stereochemistry.



NO 639711-61-5 NCMPUS  
OR Dose: N-[118]-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-oxopropyl-N'-[2,6-dichlorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.

117 ASSEMBY 8 OF 8 NCMPUS COPYRIGHT 2008 ACS on STM (Continued)



NO 639711-61-6 NCMPUS  
OR Dose: N-[118]-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-oxopropyl-N'-[4-chlorophenyl]- (CA INDEX NAME)

Absolute stereochemistry.




NO 639711-61-7 NCMPUS  
OR Dose: N-[118]-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-oxopropyl-N'-[2,6-dichlorophenyl]- (CA INDEX NAME)

Absolute stereochemistry.

117 ASSEMBY 8 OF 8 NCMPUS COPYRIGHT 2008 ACS on STM (Continued)


NO 639711-61-8 NCMPUS  
OR Dose: N-[118]-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-oxopropyl-N'-[4-(3-chlorophenyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



NO 639711-61-9 NCMPUS  
OR Dose: N-[118]-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-oxopropyl-N'-[4-(3-chlorophenyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



NO 639711-61-10 NCMPUS  
OR Dose: N-[118]-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-oxopropyl-N'-[2,6-dichlorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.

117 ASSEMBY 8 OF 8 NCMPUS COPYRIGHT 2008 ACS on STM (Continued)



NO 639711-61-11 NCMPUS  
OR Dose: N-[118]-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-oxopropyl-N'-[4-(3,5-difluorophenyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




NO 639711-61-12 NCMPUS  
OR Dose: N-[118]-1-[(1,4'-bipiperidin-1'-yl)acarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-piperidinyl]-3-oxopropyl-N'-[4-(3,5-difluorophenyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




117 ANSWER 8 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-14-0 NOVELUS  
CN Drex. W-[[18]-1-[(1,4'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-propenyl]-4'-cyclohexenyl]-1- (CN INDEX NAME)]


Absolute stereochemistry.



RD 63712-14-1 NOVELUS  
CN Drex. W-[[18]-1-[(1,4'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-propenyl]-4'-cyclohexenyl]-1- (CN INDEX NAME)]


Absolute stereochemistry.

117 ANSWER 8 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-14-2 NOVELUS  
CN Drex. W-[[18]-1-[(1,4'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-propenyl]-4'-cyclohexenyl]-1- (CN INDEX NAME)]


Absolute stereochemistry.



RD 63712-14-3 NOVELUS  
CN Drex. W-[[18]-1-[(1,4'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-propenyl]-4'-cyclohexenyl]-1- (CN INDEX NAME)]


Absolute stereochemistry.

117 ANSWER 8 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-14-4 NOVELUS  
CN Drex. W-[[18]-1-[(1,4'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-propenyl]-4'-cyclohexenyl]-1- (CN INDEX NAME)]


Absolute stereochemistry.



RD 63712-14-5 NOVELUS  
CN Drex. W-[[18]-1-[(1,4'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-propenyl]-4'-cyclohexenyl]-1- (CN INDEX NAME)]


Absolute stereochemistry.

117 ANSWER 8 OF 8 NOVELUS COPYRIGHT 2008 ACS on STM (Continued)



RD 63712-14-6 NOVELUS  
CN Drex. W-[[18]-1-[(1,4'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-propenyl]-4'-cyclohexenyl]-1- (CN INDEX NAME)]


Absolute stereochemistry.



RD 63712-14-7 NOVELUS  
CN Drex. W-[[18]-1-[(1,4'-bipiperidin-3'-ylcarbonyl)-3-[4-(2,4-dihydro-2-oxo-3(2H)-quinoxalinyl)-5-propenyl]-4'-cyclohexenyl]-1- (CN INDEX NAME)]


Absolute stereochemistry.

117 ANSHER 8 OF 8 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635712-14-0 NCAPLUS  
 CN Data: N=([18]-1-((1,4'-bipiperidin-1'-yl)-2-oxo-1,2-diphenylethane-1-one)-3-(4-chlorophenyl)-4-chlorophenyl)-N'-(4-chlorophenyl)-2-oxo-1,2-diphenylethane-1-one])- (CN ENDS NAME)


Absolute stereochemistry.



RD 635712-15-0 NCAPLUS  
 CN Data: N=([18]-1-((1,4'-bipiperidin-1'-yl)-2-oxo-1,2-diphenylethane-1-one)-3-(4-chlorophenyl)-4-chlorophenyl)-N'-(4-chlorophenyl)-2-oxo-1,2-diphenylethane-1-one])- (CN ENDS NAME)


Absolute stereochemistry.

117 ANSHER 8 OF 8 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635712-16-0 NCAPLUS  
 CN Data: N=([18]-1-((1,4'-bipiperidin-1'-yl)-2-oxo-1,2-diphenylethane-1-one)-3-(4-chlorophenyl)-4-chlorophenyl)-N'-(4-chlorophenyl)-2-oxo-1,2-diphenylethane-1-one])- (CN ENDS NAME)


Absolute stereochemistry.



RD 635712-17-0 NCAPLUS  
 CN Data: N=([18]-1-((1,4'-bipiperidin-1'-yl)-2-oxo-1,2-diphenylethane-1-one)-3-(4-chlorophenyl)-4-chlorophenyl)-N'-(4-chlorophenyl)-2-oxo-1,2-diphenylethane-1-one])- (CN ENDS NAME)


Absolute stereochemistry.

117 ANSHER 8 OF 8 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635712-18-0 NCAPLUS  
 CN Data: N=([18]-1-((1,4'-bipiperidin-1'-yl)-2-oxo-1,2-diphenylethane-1-one)-3-(4-chlorophenyl)-4-chlorophenyl)-N'-(4-chlorophenyl)-2-oxo-1,2-diphenylethane-1-one])- (CN ENDS NAME)


Absolute stereochemistry.



RD 635712-19-0 NCAPLUS  
 CN Data: N=([18]-1-((1,4'-bipiperidin-1'-yl)-2-oxo-1,2-diphenylethane-1-one)-3-(4-chlorophenyl)-4-chlorophenyl)-N'-(4-chlorophenyl)-2-oxo-1,2-diphenylethane-1-one])- (CN ENDS NAME)


Absolute stereochemistry.

117 ANSHER 8 OF 8 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



RD 635712-20-0 NCAPLUS  
 CN Data: N=([18]-1-((1,4'-bipiperidin-1'-yl)-2-oxo-1,2-diphenylethane-1-one)-3-(4-chlorophenyl)-4-chlorophenyl)-N'-(4-chlorophenyl)-2-oxo-1,2-diphenylethane-1-one])- (CN ENDS NAME)


Absolute stereochemistry.



RD 635712-21-0 NCAPLUS  
 CN Data: N=([18]-1-((1,4'-bipiperidin-1'-yl)-2-oxo-1,2-diphenylethane-1-one)-3-(4-chlorophenyl)-4-chlorophenyl)-N'-(4-chlorophenyl)-2-oxo-1,2-diphenylethane-1-one])- (CN ENDS NAME)


Absolute stereochemistry.

117 ANSWER 8 OF 8 NCMPUS COPYRIGHT 2008 ACS on BTH (Continued)



RN 63712-12-5 NCMPUS  
CN Data:  $M = [148-1-(1,4'-\text{bis(piperidin-1'-yl)-2-(4-(1,4-dihydro-2-oxo-2(1H)-pyridazinyl)-5-pyridinyl)-3-methyl-1H-1,4-bisoxo-2-antipyranyloxy]-4-bromo-2-antipyranyloxy}] =$  (CA INDEX NAME)


Absolute stereochemistry:



RN 63712-13-3 NCMPUS  
CN Data:  $M = [148-1-(1,4'-\text{bis(piperidin-1'-yl)-2-(4-(1,4-dihydro-2-oxo-2(1H)-pyridazinyl)-5-pyridinyl)-3-methyl-1H-1,4-bisoxo-2-antipyranyloxy]-4-bromo-2-antipyranyloxy}] =$  (CA INDEX NAME)


Absolute stereochemistry:

117 ANSWER 8 OF 8 NCMPUS COPYRIGHT 2008 ACS on BTH (Continued)



RN 63712-14-4 NCMPUS  
CN Data:  $M = [148-1-(1,4'-\text{bis(piperidin-1'-yl)-2-(4-(1,4-dihydro-2-oxo-2(1H)-pyridazinyl)-5-pyridinyl)-3-methyl-1H-1,4-bisoxo-2-antipyranyloxy]-4-bromo-2-antipyranyloxy}] =$  (CA INDEX NAME)


Absolute stereochemistry:



RN 63712-15-5 NCMPUS  
CN Data:  $M = [148-1-(1,4'-\text{bis(piperidin-1'-yl)-2-(4-(1,4-dihydro-2-oxo-2(1H)-pyridazinyl)-5-pyridinyl)-3-methyl-1H-1,4-bisoxo-2-antipyranyloxy]-4-bromo-2-antipyranyloxy}] =$  (CA INDEX NAME)


Absolute stereochemistry:

117 ANSWER 8 OF 8 NCMPUS COPYRIGHT 2008 ACS on BTH (Continued)



RN 63712-16-8 NCMPUS  
CN Data:  $M = [148-1-(1,4'-\text{bis(piperidin-1'-yl)-2-(4-(1,4-dihydro-2-oxo-2(1H)-pyridazinyl)-5-pyridinyl)-3-methyl-1H-1,4-bisoxo-2-antipyranyloxy]-4-bromo-2-antipyranyloxy}] =$  (CA INDEX NAME)

Absolute stereochemistry:



RN CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORM

```
-> b uspatall
FILE 'USPATFULL' ENTERED AT 14:15:09 ON 06 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 14:15:09 ON 06 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:15:09 ON 06 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

-> d bib abs hitrn fhitstr 120 tot
```



-> d bib abs hitrn fhitstr 121 tot





PT	42-00170002101	A1	20070426
AC	200425-00130046	A1	20040323 (10)
	200000-00110737		20040325
			20060915 PCT 31s date
9991	200328-0010031		20030717
DT	CLASS		
FS	APPLICATION		
1/MP	KAPPE, SCHEIDTKE, MILLER & LANGSON, P.C., P.O. BOX 1907, MINNEAPOLIS, MN.		
CL	Number of Claims: 38		
ICL	87402-6902, US		
CDU	Empty Class: 11		
CHSU	No Drawings		
AS INT	7/17/78		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
* The present invention provides a urea derivative or a salt thereof.			

[illegible]


CAS INDEXING IN AVAILABLE FOR THIS PATENT.

12 55416-45-49  
[preparation of urea derivs. as activated blood coagulation factor X  
inhibitors]

12 55416-46-49  
[preparation of urea derivs. as activated blood coagulation factor X  
inhibitors]

12 55416-45-8 US PATENT  
CN Urea, N-[4-chlorophenyl]-N'-[11R]-3,2,2-dimethyl-3-[(2-oxo)-6'-bipiperidin-  
3'-yl]-carbonyl]propyl)- (CA INDEX NAME)


Abstract stereochemistry:-



10 ANKOR 7 OF 31 ESPAFETA ON STM  
 11 2008 149981 USTAFETA  
 12 Disclosure on Justice in Cambodia  
 13 Song, Jongphong, Phnom Penh, CA, UNITED STATES  
 14 Hon. King-Tan, Phnom Penh, CA, UNITED STATES  
 15 Branta, Canada, Myanmar, CA, UNITED STATES  
 16 Sordorff, Robert H., 1412 Moon Way, CA, UNITED STATES  
 17 Phnom Penh, Cambodia, CA, UNITED STATES  
 18 (C) 31 (compensation)  
 19 US-33410187  
 20 100906-001289298 100901207 (40)  
 21 100906-001289298 100901207 (40)  
 22 100906-001289298 100901207 (40)  
 23 100906-001289298 100901207 (40)  
 24 100906-001289298 100901207 (40)  
 25 100906-001289298 100901207 (40)  
 26 100906-001289298 100901207 (40)  
 27 100906-001289298 100901207 (40)  
 28 100906-001289298 100901207 (40)  
 29 100906-001289298 100901207 (40)  
 30 100906-001289298 100901207 (40)  
 31 100906-001289298 100901207 (40)  
 32 100906-001289298 100901207 (40)  
 33 100906-001289298 100901207 (40)  
 34 100906-001289298 100901207 (40)  
 35 100906-001289298 100901207 (40)  
 36 100906-001289298 100901207 (40)  
 37 100906-001289298 100901207 (40)  
 38 100906-001289298 100901207 (40)  
 39 100906-001289298 100901207 (40)  
 40 100906-001289298 100901207 (40)  
 41 100906-001289298 100901207 (40)  
 42 100906-001289298 100901207 (40)  
 43 100906-001289298 100901207 (40)  
 44 100906-001289298 100901207 (40)  
 45 100906-001289298 100901207 (40)  
 46 100906-001289298 100901207 (40)  
 47 100906-001289298 100901207 (40)  
 48 100906-001289298 100901207 (40)  
 49 100906-001289298 100901207 (40)  
 50 100906-001289298 100901207 (40)  
 51 100906-001289298 100901207 (40)  
 52 100906-001289298 100901207 (40)  
 53 100906-001289298 100901207 (40)  
 54 100906-001289298 100901207 (40)  
 55 100906-001289298 100901207 (40)  
 56 100906-001289298 100901207 (40)  
 57 100906-001289298 100901207 (40)  
 58 100906-001289298 100901207 (40)  
 59 100906-001289298 100901207 (40)  
 60 100906-001289298 100901207 (40)  
 61 100906-001289298 100901207 (40)  
 62 100906-001289298 100901207 (40)  
 63 100906-001289298 100901207 (40)  
 64 100906-001289298 100901207 (40)  
 65 100906-001289298 100901207 (40)  
 66 100906-001289298 100901207 (40)  
 67 100906-001289298 100901207 (40)  
 68 100906-001289298 100901207 (40)  
 69 100906-001289298 100901207 (40)  
 70 100906-001289298 100901207 (40)  
 71 100906-001289298 100901207 (40)  
 72 100906-001289298 100901207 (40)  
 73 100906-001289298 100901207 (40)  
 74 100906-001289298 100901207 (40)  
 75 100906-001289298 100901207 (40)  
 76 100906-001289298 100901207 (40)  
 77 100906-001289298 100901207 (40)  
 78 100906-001289298 100901207 (40)  
 79 100906-001289298 100901207 (40)  
 80 100906-001289298 100901207 (40)  
 81 100906-001289298 100901207 (40)  
 82 100906-001289298 100901207 (40)  
 83 100906-001289298 100901207 (40)  
 84 100906-001289298 100901207 (40)  
 85 100906-001289298 100901207 (40)  
 86 100906-001289298 100901207 (40)  
 87 100906-001289298 100901207 (40)  
 88 100906-001289298 100901207 (40)  
 89 100906-001289298 100901207 (40)  
 90 100906-001289298 100901207 (40)  
 91 100906-001289298 100901207 (40)  
 92 100906-001289298 100901207 (40)  
 93 100906-001289298 100901207 (40)  
 94 100906-001289298 100901207 (40)  
 95 100906-001289298 100901207 (40)  
 96 100906-001289298 100901207 (40)  
 97 100906-001289298 100901207 (40)  
 98 100906-001289298 100901207 (40)  
 99 100906-001289298 100901207 (40)  
 100 100906-001289298 100901207 (40)

NCL Energylog Chain 1  
 DRAWN & Drawing Page(s)  
 13 CH 2197  
 CAN INFORMATION IS AVAILABLE FOR THIS MATERIAL.  
 AB The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof, which are useful in the treatment of cancer. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired growths and/or spread of malignant cells, the administration of a blood transfusion, and the use of such compounds in the treatment of cancer.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 92152-22-89  
     [preparation of amino acid thioester deriv. as factor Ee inhibitors]  
 IT 92032-22-89  
     [preparation of amino acid thioester deriv. as factor Ee inhibitors]  
 SN 92152-22-89  
 CN 92152-22-89  
 DE 92152-22-89  
 EN 92152-22-89  
 ES 92152-22-89  
 FR 92152-22-89  
 GB 92152-22-89  
 GR 92152-22-89  
 IL 92152-22-89  
 IN 92152-22-89  
 JP 92152-22-89  
 KR 92152-22-89  
 NL 92152-22-89  
 NO 92152-22-89  
 PL 92152-22-89  
 PT 92152-22-89  
 RO 92152-22-89  
 RU 92152-22-89  
 SE 92152-22-89  
 SI 92152-22-89  
 TR 92152-22-89  
 UA 92152-22-89  
 US 92152-22-89  
 VN 92152-22-89  
 ZK 92152-22-89  
 ZN 92152-22-89  
 ZS 92152-22-89  
 ZT 92152-22-89  
 ZZ 92152-22-89  
 AA 92152-22-89  
 AB 92152-22-89  
 AC 92152-22-89  
 AD 92152-22-89  
 AE 92152-22-89  
 AF 92152-22-89  
 AG 92152-22-89  
 AI 92152-22-89  
 AJ 92152-22-89  
 AK 92152-22-89  
 AL 92152-22-89  
 AM 92152-22-89  
 AN 92152-22-89  
 AO 92152-22-89  
 AP 92152-22-89  
 AQ 92152-22-89  
 AR 92152-22-89  
 AS 92152-22-89  
 AT 92152-22-89  
 AU 92152-22-89  
 AV 92152-22-89  
 AW 92152-22-89  
 AX 92152-22-89  
 AY 92152-22-89  
 AZ 92152-22-89  
 BA 92152-22-89  
 BB 92152-22-89  
 BC 92152-22-89  
 BD 92152-22-89  
 BE 92152-22-89  
 BF 92152-22-89  
 BG 92152-22-89  
 BH 92152-22-89  
 BI 92152-22-89  
 BJ 92152-22-89  
 BK 92152-22-89  
 BL 92152-22-89  
 BM 92152-22-89  
 BN 92152-22-89  
 BO 92152-22-89  
 BP 92152-22-89  
 BQ 92152-22-89  
 BR 92152-22-89  
 BS 92152-22-89  
 BT 92152-22-89  
 BU 92152-22-89  
 BV 92152-22-89  
 BW 92152-22-89  
 BY 92152-22-89  
 BZ 92152-22-89  
 CA 92152-22-89  
 CB 92152-22-89  
 CC 92152-22-89  
 CD 92152-22-89  
 CE 92152-22-89  
 CF 92152-22-89  
 CG 92152-22-89  
 CH 92152-22-89  
 CI 92152-22-89  
 CJ 92152-22-89  
 CK 92152-22-89  
 CL 92152-22-89  
 CM 92152-22-89  
 CN 92152-22-89  
 CO 92152-22-89  
 CP 92152-22-89  
 CQ 92152-22-89  
 CR 92152-22-89  
 CS 92152-22-89  
 CT 92152-22-89  
 CU 92152-22-89  
 CV 92152-22-89  
 CW 92152-22-89  
 CX 92152-22-89  
 CY 92152-22-89  
 CZ 92152-22-89  
 DA 92152-22-89  
 DB 92152-22-89  
 DC 92152-22-89  
 DD 92152-22-89  
 DE 92152-22-89  
 DF 92152-22-89  
 DG 92152-22-89  
 DH 92152-22-89  
 DI 92152-22-89  
 DJ 92152-22-89  
 DK 92152-22-89  
 DL 92152-22-89  
 DM 92152-22-89  
 DN 92152-22-89  
 DO 92152-22-89  
 DP 92152-22-89  
 DQ 92152-22-89  
 DR 92152-22-89  
 DS 92152-22-89  
 DT 92152-22-89  
 DU 92152-22-89  
 DV 92152-22-89  
 DW 92152-22-89  
 DX 92152-22-89  
 DY 92152-22-89  
 DZ 92152-22-89  
 EA 92152-22-89  
 EB 92152-22-89  
 EC 92152-22-89  
 ED 92152-22-89  
 EE 92152-22-89  
 EF 92152-22-89  
 EG 92152-22-89  
 EH 92152-22-89  
 EI 92152-22-89  
 EJ 92152-22-89  
 EK 92152-22-89  
 EL 92152-22-89  
 EM 92152-22-89  
 EN 92152-22-89  
 EO 92152-22-89  
 EP 92152-22-89  
 EQ 92152-22-89  
 ER 92152-22-89  
 ES 92152-22-89  
 ET 92152-22-89  
 EU 92152-22-89  
 EV 92152-22-89  
 EW 92152-22-89  
 EX 92152-22-89  
 EY 92152-22-89  
 EZ 92152-22-89  
 FA 92152-22-89  
 FB 92152-22-89  
 FC 92152-22-89  
 FD 92152-22-89  
 FE 92152-22-89  
 FF 92152-22-89  
 FG 92152-22-89  
 FH 92152-22-89  
 FI 92152-22-89  
 FJ 92152-22-89  
 FK 92152-22-89  
 FL 92152-22-89  
 FM 92152-22-89  
 FN 92152-22-89  
 FO 92152-22-89  
 FP 92152-22-89  
 FQ 92152-22-89  
 FR 92152-22-89  
 FS 92152-22-89  
 FT 92152-22-89  
 FU 92152-22-89  
 FV 92152-22-89  
 FW 92152-22-89  
 FX 92152-22-89  
 FY 92152-22-89  
 FZ 92152-22-89  
 GA 92152-22-89  
 GB 92152-22-89  
 GC 92152-22-89  
 GD 92152-22-89  
 GE 92152-22-89  
 GF 92152-22-89  
 GG 92152-22-89  
 GH 92152-22-89  
 GI 92152-22-89  
 GJ 92152-22-89  
 GK 92152-22-89  
 GL 92152-22-89  
 GM 92152-22-89  
 GN 92152-22-89  
 GO 92152-22-89  
 GP 92152-22-89  
 GQ 92152-22-89  
 GR 92152-22-89  
 GS 92152-22-89  
 GT 92152-22-89  
 GU 92152-22-89  
 GV 92152-22-89  
 GW 92152-22-89  
 GX 92152-22-89  
 GY 92152-22-89  
 GZ 92152-22-89  
 HA 92152-22-89  
 HB 92152-22-89  
 HC 92152-22-89  
 HD 92152-22-89  
 HE 92152-22-89  
 HF 92152-22-89  
 HG 92152-22-89  
 HH 92152-22-89  
 HI 92152-22-89  
 HJ 92152-22-89  
 HK 92152-22-89  
 HL 92152-22-89  
 HM 92152-22-89  
 HN 92152-22-89  
 HO 92152-22-89  
 HP 92152-22-89  
 HQ 92152-22-89  
 HR 92152-22-89  
 HS 92152-22-89  
 HT 92152-22-89  
 HU 92152-22-89  
 HV 92152-22-89  
 HW 92152-22-89  
 HX 92152-22-89  
 HY 92152-22-89



LN ANTHONY J OF BAPTIST CH OR STE  
AD 1906-1978) SHELTON.  
LT House or Pastor for Ministers  
TN Army, Thompson, Foster City, CA, UNITED STATES  
DO Dr. Bing-Yin, Hsu, San Francisco, CA, UNITED STATES  
WY James, Thomas, Foster City, CA, UNITED STATES  
MO Willie, Chaney, Houston, TX, UNITED STATES  
SC Donaldson, Robert W., 2662 Wood Rd, SAN DIEGO, UNITED STATES  
PT (In company) 106)  
DE SN-1646(106)  
AT 100595-09315031 1 26621037 (11)  
SPAZ 100595-09315031 26621037 (11)  
DE MT1151  
AT ADVOCATOR  
LT LEED THOMSON AND THOMPSON AND CHAM, TWO EMPLOYERS/OWNERS, EIGHTH  
FLORA, SAN FRANCISCO, CA, 94111-3416, US  
CLRP Number of Claims :  
SCL Employment Claim : 1  
SCL Non-Employment Claim : 0  
LAW FIRM 476  
LAW FIRM IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds represented by Formula and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Ia. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by unregulated thrombosis and methods of inhibiting the coagulation of a blood sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 851783-71-2P 851783-75-0P 851783-80-1P  
 (preparation of amino acid urea derivs. as factor Xa inhibitors)  
 IT 851783-72-2P  
 (preparation of amino acid urea derivs. as factor Xa inhibitors)  
 KR 851783-71-2 UOAPATLIT  
 CN Urea, N-(4-chlorophenyl)-N'-[1-[1,3-bis-(2-oxo-1,4'-bipiperidin-1'-yl)-1-phenyl]ethyl]- (CA INDEX NAME)  
 Absolute stereochemistry.



21 ANCHER 8 OF 11 38407416 ON STE  
 22 ANCA2018058 USAPATH  
 23 CALICITOUS QUON JEWELLERIE  
 24 CHACUVERDUE, FRANK W., CHARLOTTE, CT, UNITED STATES  
 25 CHEN, DING, MIDDLEFIELD, CT, UNITED STATES  
 26 CIVILIANO, KATA, KILLINGWORTH, CT, UNITED STATES  
 27 CONWAY, CHARLES MARK, CHESTER, CT, UNITED STATES  
 28 DEGRAT, ANDREW P., NEW HAVEN, CT, UNITED STATES  
 29 DUBOWCHIK, DONALD M., MIDDLEFIELD, CT, UNITED STATES  
 30 EARL, KATHY, CHESHAM, CT, UNITED STATES  
 31 J. JANG, KIANG SUN, BLOOMER, CT, UNITED STATES  
 32 KEDZIOR, GEORGE M., WALLACE, CT, UNITED STATES  
 33 LEE, GEORGINA, BLOOMER, CT, UNITED STATES  
 34 MANN, JOHN R., GAITHER, CT, UNITED STATES  
 35 POUNDREAU, GRADHAM, SHREVE, CT, UNITED STATES  
 36 TAYLOR, GEORGE, MIDDLEFIELD, CT, UNITED STATES  
 37 TAYLOR, KATHLEEN, MIDDLEFIELD, CT, UNITED STATES

[illegible]

```

7FS APPLICATION
LEAD STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4600, PRINCETON, NJ, 08543-1022
CLOSI Number of Claims: 48
ECL Exemplary Claim: 1
DRAHI 1 Drawing Page(s)
LW CMT 14(4)
CA INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of Formula (I) ##STR1##
as antagonists of calcitonin gene-related peptide receptors

```


["COOP+compop"], pharmacological compositions comprising them, method for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory disease such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the administration of COOP+compop.

[illegible]

IT	635711-71-69	(preparation of diacetylcyclohexyls as calcitonin gene related peptide receptor antagonists)
III	635711-71-6	(preparation of diacetylcyclohexyls as calcitonin gene related peptide receptor antagonists)



401 ASSIGNED 10 OF 11 CHARACTERS ON SITE (CONTINUED)



121 ANSWER 11 OF 11 SUBMIT OR STOP

[illegible]

**##02744** analogues of calcitonin gene-related peptide receptors ("CGRP-receptors"), pharmacological compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and also conditions the treatment of which can be affected by the expression of CGRP-receptors.

CAR INDEXING IS AVAILABLE FOR THIS PATENT.

635711-71-89 635711-72-79 635711-73-49  
 635711-74-89 635711-75-89 635711-76-89  
 635711-77-89 635711-78-89 635711-79-89  
 635711-80-89 635711-81-89 635711-82-89  
 635711-83-89 635711-84-89 635711-85-89  
 635711-86-89 635711-87-89 635711-88-89  
 635711-89-89 635711-90-89 635711-91-89  
 635711-92-89 635711-93-89 635711-94-89  
 635711-95-89 635711-96-89 635711-97-89  
 635711-98-89 635711-99-89 635712-00-00  
 635712-01-00 635712-02-00 635712-03-00  
 635712-04-00 635712-05-00 635712-06-00  
 635712-07-00 635712-08-00 635712-09-00  
 635712-10-00 635712-11-00 635712-12-00  
 635712-13-00 635712-14-00 635712-15-00  
 635712-16-00 635712-17-00 635712-18-00  
 635712-19-00 635712-20-00 635712-21-00  
 635712-22-00 635712-23-00 635712-24-00  
 635712-25-00 635712-26-00 635712-27-00  
 635712-28-00 635712-29-00 635712-30-00  
 635712-31-00 635712-32-00 635712-33-00  
 635712-34-00 635712-35-00 635712-36-00

435712-34-40  
(preparation of diazoheterocycles as calcitonin gene related peptide  
receptor antagonists)  
re 435711-33-40

322 ANSWER 11 OF 11 ISPART on 5TH (Continued)


(prepn. of diazabicyclopentadienes as calcitonin gene related peptide receptor antagonists)

```

IN  635711-71-6  USMA32
CS  Urea, N-[1-[1-[1-(4'-bis(piperidin)-3'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-
   3[3H]-quinoxalinsyl)-2-piperidinyl]-2-oxopropyl]-N'-2-naphthalenyl]- (CR
[NOE NAME]

```

### Absolute stereochemistry



-> d his

(FILE 'HOME' ENTERED AT 14:02:25 ON 06 MAY 2008)

L1 FILE 'HCAPLUS' ENTERED AT 14:03:03 ON 06 MAY 2008  
1 US20070123509/PN

FILE 'REGISTRY' ENTERED AT 14:03:18 ON 06 MAY 2008

L2 FILE 'HCAPLUS' ENTERED AT 14:03:18 ON 06 MAY 2008  
TRA L1 1- RN : 72 TERMS

L3 FILE 'REGISTRY' ENTERED AT 14:03:18 ON 06 MAY 2008  
72 SEA L2

L4 27 L3 AND >-2 NC5/ES

L5 26 L4 AND NR>=3

L6 STR

L7 0 L6

L8 419318 >-2 NC5/ES

L9 83515 >-2 46.156.1/RID

L10 0 L6 SAM SUB=L8

L11 101 L6 FULL SUB=L8

SAV TEM J850GI/A L11

L12 100 L11 AND L9

L13 1 L11 NOT L12

L14 24 L12 AND L3

L15 76 L12 NOT L14

FILE 'HCAPLUS' ENTERED AT 14:12:24 ON 06 MAY 2008

L16 2 L14

L17 8 L15

FILE 'HCAOLD' ENTERED AT 14:12:40 ON 06 MAY 2008

L18 0 L14

L19 0 L15

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 14:12:51 ON 06 MAY 2008

L20 1 L14

L21 11 L15

=>